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Abstract 
Recurrent miscarriage (RM) is defined as three or more consecutive pregnancy failures 
and is estimated to affect ~1% of couples trying to conceive. The cause of RM remains 
unknown in approximately 50% of cases although much work has been done in the past  
to identify the underlying mechanisms. In this study, it was hypothesized that some of the 
underlying factors yet to be discovered are genetic. 
 
The aim of this study was to obtain new information on genetic causes of RM. The aim 
was to search for mutations in genes known to cause miscarriage in animal models and 
thereby find new genetic causes for unexplained miscarriages in humans. Four candidate 
genes – Amnionless (AMN), Endothelial protein C receptor (EPCR), Thrombomodulin 
(TM), and p53 – were chosen for the study as they have all been considered to be crucial 
for normal embryonic development in the mouse. In addition, the mitochondrial genome 
was studied because mitochondria are involved in processes important in early 
development. Furthermore, sex chromosome characteristics suggested to underlie 
miscarriage were also studied. 
 
A total of 40 couples and 8 women with unexplained RM were collected for this study. 
The patients were screened for mutations in the AMN, TM and EPCR genes using dHPLC.  
Six interesting exonic and potential splice site disrupting variations were detected in these 
genes, namely c.363G>A, c.843+11C>T, c.1339_1344dup, and c.1170-6C>T in AMN, 
c.1728+23_+40del in TM, and c.323-9_336dup in EPCR. Two of these variations, 
c.363G>A and c.843+11C>T were more frequent in RM women compared to controls. 
However, their phenotypic effects cannot be determined without further investigations. 
While most variations in the AMN, TM and EPCR genes were identified in both patients 
and controls and are likely to be silent polymorphisms, others may have functional 
significance or modifier effects in combination with mutations or polymorphisms in other 
genes.  
 
An association between the C11992A polymorphism of the p53 gene and RM was 
detected. The results indicate that women carrying the C/A or A/A genotype have a 
twofold higher risk for RM than women with a C/C genotype. This strengthens the results 
of previous studies reporting that p53 sequence variations may cause miscarriage. The role 
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of variation C11992A in embryonic development is, however, difficult to predict without 
further studies. The role of p53 in RM was also investigated through expression analysis 
of p53 in placental tissue. The results showed normal expression of p53 in the samples 
studied.  
 
When screening the mitochondrial genome a heteroplasmic mtDNA variation was 
found in 13 (27%) RM women and 9 (19%) control women, which was unexpected as 
heteroplasmic variations are reported to be rare. One novel variation within the coding 
regions of the mitochondrial genome was detected. In addition, 18 previously reported 
polymorphisms were identified. Although the detected variations are likely to be neutral 
polymorphisms, a role in the aetiology of miscarriage cannot be excluded as some mtDNA 
variations may be pathogenic only when a threshold is reached.  
 
Recent publications have reported skewed X chromosome inactivation and Y 
chromosome microdeletions to be associated with RM. Therefore, these sex chromosome 
abnormalities in the context of RM were investigated. No association between skewed X 
chromosome inactivation or Y chromosome microdeletions and RM in the Finnish 
patients studied were detected. 
 
In addition, data on ancestral birthplaces of the patients were collected to study any 
possible geographic clustering, which would indicate a common predisposing factor. The 
results showed clustering of the birthplaces in eastern Finland in a subset of patients. This 
suggests a possibility of an enriched susceptibility gene which may contribute to RM. 
These results encourage further studies to determine new genetic factors contributing to 
the aetiology of RM. 
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Introduction 
Miscarriages are the most common complication of pregnancy, affecting approximately 
15% of all clinically recognized pregnancies in the general population. The exact 
frequency of miscarriages is, however, unknown as miscarriages frequently occur before 
the woman is aware of her pregnancy. It is estimated that more pregnancies are lost 
spontaneously than are actually carried to term (Rai and Regan, 2006; Stephenson and 
Kutteh, 2007). Most of the miscarriages are sporadic and non-recurrent, and are often 
caused by chromosome abnormalities in the foetus (Dhont, 2003). Recurrent miscarriage 
(RM), defined as three consecutive pregnancy failures, is estimated to affect ~1% of all 
couples trying to conceive (Li et al., 2002; Rai and Regan, 2006).  
 
There are numerous factors that may cause RM, but the underlying problem often 
remains undetected. Although much work has been done to identify the underlying 
mechanisms, the cause of miscarriage can be identified in only ~50% of cases. The known 
causes of RM include chromosomal and metabolic abnormalities, uterine anomalies, and 
immunologic factors (Li et al., 2002; Rai and Regan, 2006). Even though RM is a 
heterogeneous condition and the progress in identifying causative factors has been slow, 
the repetitive pregnancy losses in some couples and the high percentage of unexplained 
RM indicate that there are specific underlying causes yet to be found.  
 
This study was conducted to gain further knowledge concerning genetic causes of RM.  
Identification of the underlying factors is crucial for the development of more successful 
treatment and improvement of the outcome of future pregnancies in women experiencing 
RM. Genetic factors causing RM are, however, difficult to study because the foetus is lost  
at an early stage of development and is therefore difficult to examine. Consequently, most 
of the studies conducted on RM in general, and in this thesis work, are based on studying 
the couples experiencing the miscarriages. We hypothesized that several genetic factors 
such as mutations in genes, either identified from animal models or regulating functions 
important in different stages of early foetal development, or abnormalities in the sex 
chromosomes may underlie the miscarriages in the couples studied.  
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Review of the literature 
1 Early human embryonic development 
1.1 Fertilization 
The development of a human being starts from a single cell, a zygote, which results from 
an ovum being fertilized by a spermatozoon. Fertilization occurs in the fallopian tube 
within 48 hours
 
of ovulation. After fertilization, a series of symmetrical cell divisions 
create a mass of 12 to 16 totipotent cells, the morula, which is still enclosed within the 
zona pellucida (Norwitz et al., 2001; Sariola et al., 2003). The
 
morula enters the uterine 
cavity approximately three
 
days after fertilization. The appearance of a fluid filled inner
 
cavity within the mass of cells marks the transition from a morula
 
to a blastocyst and is 
accompanied by cellular differentiation (Norwitz et al., 2001; Wang and Dey, 2006). The 
first differentiation event gives rise to trophoblasts, specialized epithelial cells that give 
rise to extraembryonic
 
structures, including the placenta. The remaining cells segregate at 
one pole of the embryo to form the inner cell mass (ICM) (Figure 1). Within three days of 
entering the
 
uterine cavity, the embryo hatches from the zona pellucida, thereby exposing
 
its trophoblast cells, which enables implantation (Norwitz et al., 2001; Sariola et al., 2003; 
Wang and Dey, 2006).
  
1.2 Implantation 
The newly formed zygote has a discrete time frame in which it must prepare itself for 
implantation. Preparation begins upon oocyte fertilization and takes approximately 6 to 7 
days. During this time successive cell division occurs, and the outer trophoblast cells of 
the blastocyst differentiate into cytotrophoblasts which diverge into villous and invasive 
subtypes forming the building blocks of the placenta (Norwitz et al., 2001; Vitiello and 
Patrizio, 2007). At the same time, when the blastocyst prepares itself for implantation, the 
uterus becomes receptive. Uterine receptivity is defined as the state during the period
 
of 
endometrial maturation and proliferation when the blastocyst can become implanted. 
Multiple signals synchronize the development of the blastocyst
 
and the preparation of the 
uterus. Of the many aspects
 
of the synchronization process, the role of steroid hormones
 
is 
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the best understood. Peptide hormones, growth factors, and cytokines also have roles in 
the process.
 
The cascade of signalling events that occur in both foetal and maternal tissues 
establishes an appropriate environment critical to the development and survival of the 
foetus (Norwitz et al., 2001; Wang and Dey, 2006; Vitiello and Patrizio, 2007).  
 
Implantation occurs in three stages. The first stage is the initial adhesion of the 
blastocyst
 
to the uterine wall. The next stage is characterized
 
by increased physical 
interaction between the blastocyst and
 
the uterine epithelium. Shortly thereafter invasion 
begins
 
and syncytiotrophoblasts, the outer layer of the trophoblasts, penetrate the uterine 
epithelium (Wang and Dey, 2006; Chavatte-Palmer and Guillomot, 2007; Vitiello and 
Patrizio, 2007). By the 10th day after conception, the blastocyst is completely
 
embedded 
in the stromal tissue of the uterus as the uterine epithelium
 
has regrown to cover the site of 
implantation (Norwitz et al., 2001). The interaction between an activated blastocyst and a 
receptive
 
uterus is part of a complex process that leads to implantation
 
and the early stages 
of placental development. Failure
 
to synchronize the processes involved in these 
interactions
 
results in failure of implantation (Cross et al., 1994; Wang and Dey, 2006; 
Chavatte-Palmer and Guillomot, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The early stages of human development. A) An unfertilized egg cell is fertilized in the fallopian 
tube by a sperm cell leading to B) a fertilized cell containing both the maternal and paternal pronuclei. The 
cell undergoes cleavage to C) the 2-cell stage, D) the 4-cell stage and E) the 8-cell stage, which is reached 
two to three days after fertilization. F) The morula enters the uterine cavity approximately three days after 
fertilization. G) Implantation of the blastocyst, consisting of a blastocyst cavity, trophoblast cells and the 
inner cell mass, into the uterine epithelium is initiated around seven days after fertilization. Modified from 
Wang and Dey, 2006. 
 
  
 
 
14 
1.3 Placentation 
The placenta is the first organ to form during mammalian embryogenesis. The placenta is 
a vital organ without which the embryo cannot survive in the uterine environment. The 
function of the placenta during early gestation is primarily to mediate implantation of the 
embryo into the uterus. After implantation, the major function of the placenta is to 
mediate, as well as to regulate, nutrient uptake from the mother to the foetus. It also 
establishes the interface for gas exchange between the maternal and foetal circulation. 
Another important function of the placenta is the
 
regulation of the maternal immune 
response so that the foetal
 
semi-allograft is tolerated during pregnancy. The placenta also 
acts as an important source of hormones and growth factors that are needed for the initial 
maternal recognition of pregnancy (Cross et al., 1994; Cross, 2006; Sadler et al., 2006). 
 
Because the placenta is critical for survival it is very sensitive to disruption. Genetic or 
environmental factors that affect the development of the placenta are associated with poor 
pregnancy outcome. Abnormal expression of specific regulatory genes in the placenta and 
abnormal functions of imprinted genes may cause placental dysfunction (Coan et al., 
2005). Abnormalities in placental functions can lead to a variety of problems including 
implantation failure, placental insufficiency, foetal growth retardation and embryonic 
death. Complications that become apparent relatively late in pregnancy may actually 
reflect errors that occurred already during placental development (Cross et al., 1994; 
Rossant and Cross, 2001; Cross, 2006). 
1.4 Gastrulation and organogenesis 
While the syncytiotrophoblasts start to penetrate into the wall of the uterus during 
implantation, the embryoblast/ICM also continues developing. The embryoblast forms a 
bilaminar embryo, composed of the epiblast and the hypoblast. The hypoblast forms the 
yolk sac. The epiblast undergoes gastrulation at approximately day 16 following 
fertilization. Gastrulation establishes the three germ layers—the endoderm, ectoderm, and 
mesoderm—all of which will give rise to various organ systems. The mesoderm also 
interacts with the trophoblast tissue to form the umbilical cord (Cross et al., 1994; Sadler 
et al., 2006). At this point the actual embryonic phase starts and lasts from the third week 
until the eighth week following fertilization. The organ systems differentiate at greatly 
varying rates during this phase. For example, the circulatory system is largely functional at 
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the end of this period, whereas the nervous system continues to undergo massive cell 
division and is only beginning to establish functional connections (Sadler et al., 2006). 
The remainder of human development, from weeks nine to thirty-eight, is called the foetal 
period. During this period the embryo acquires its human appearance. The foetal period is 
characterized by rapid growth and continued tissue and organ differentiation (Sariola et 
al., 2003; Sadler et al., 2006). 
2 Recurrent miscarriage 
Human reproduction entails a fundamental paradox: although it
 
is critical for the survival 
of the species, the process is relatively
 
inefficient. Maximal fecundity (the probability of 
fertilization
 
during one menstrual cycle) is approximately 30%. In addition, although much 
research and many advances have been made in reproductive medicine during the past 
decades, miscarriage, the spontaneous loss of a pregnancy before the foetus reaches 
viability, remains the most common complication of pregnancy (Clark et al., 2001; Pandey 
et al., 2004). 
 
There are two types of miscarriage; sporadic and recurrent. In the general population 
~15% of all clinically recognized pregnancies end in miscarriage (Stray-Pederson and 
Stray-Perderson, 1984; Nybo Andersen et al., 2000). However, the rate of miscarriage 
may be as high as 50-60% if the undetected, very early pregnancy losses occurring within 
the first weeks following gestation are taken into account (Roberts and Lowe, 1975; 
Wilcox et al., 1988). Of the pregnancies that are lost, ~70-75% are caused by failures of 
implantation or early placentation and are therefore not clinically
 
recognized as 
pregnancies. As a consequence, only
 
about half of all conceptions advance into the second 
trimester of pregnancy (Figure 2) (Rai and Regan, 2006).  
 
RM is estimated to occur in 1-2% of all couples (Tulppala et al., 1993; Katz and 
Kuller, 1994), but the exact prevalence of RM is dependent on its definition. RM is often 
defined as the occurrence of three or more consecutive, clinically detectable pregnancy 
failures before the 20
th
 week of gestation (Li et al., 2002b; Quenby et al., 2002; Pandey et 
al., 2004). However, some studies have also included patients with two miscarriages 
(Laskin et al., 1997; Stephenson et al., 1998) and in some studies the miscarriages were 
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not necessarily consecutive. This increases the prevalence of RM up to 5% of all couples 
trying to conceive (Rai and Regan, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Number of conceptions expected to reach different stages of pregnancy. Of all fertilized oocytes 
only about half result in a livebirth. Most of the pregnancies are lost during early stages of development. 
Modified from Rai and Regan, 2006. 
2.1 Identifiable causes of miscarriage 
The repetitive miscarriages in some couples suggest that certain women are at particular 
risk of losing their pregnancy and that there must be an underlying explanation for this. 
Even though much work has been done to identify these underlying mechanisms, the 
aetiology of miscarriage is still unknown in many cases. Additionally, on an individual 
level the exact reason for a particular miscarriage is rarely defined. Despite the extensive 
medical testing and experimental treatments that many patients undergo, the cause often 
remains unclear (Plouffe et al., 1992; Clifford et al., 1994; Carrington et al., 2005). The 
main identifiable causes of miscarriage include the following categories (Table 1):  
 
Uterine pathology; Uterine defects, such as uterine anomalies and fibroids, can 
predispose to miscarriage by affecting implantation (Bulletti et al., 1996; Bajekal and Li, 
2000).  
 
Endocrine abnormalities; Following implantation, the maintenance of the pregnancy is 
dependent on a range of endocrinological events that will eventually aid in the successful 
growth and development of the endometrium and the foetus (Potdar and Konje, 2005; 
Arredondo and Noble, 2006). Normal endometrial development and maturation is 
dependent on steroid hormones, particularly oestrogen and progesterone. Therefore, 
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miscarriage can be a result of subnormal hormone production or abnormal endometrial 
response to circulating steroid hormones (Li et al., 2002a; Arredondo and Noble, 2006).  
In addition, several other maternal endocrinological abnormalities such as uncontrolled 
diabetes (Mills et al., 1988), high androgen levels (Okon et al., 1998; Bussen et al., 1999), 
hyperprolactinaemia (Tal et al., 1991), thyroid dysfunction (Roberts and Murphy, 2000), 
and obesity (Wang JX et al., 2002) have been implicated as aetiological factors for RM.  
 
Immunological factors; Since the conceptus displays paternal gene products and 
antigens, it is possible that the maternal
 
immune system recognizes these as foreign, 
resulting in an immune response (Dalton et al., 1998; Hill and Choi, 2000). Survival of the 
semiallogenic foetus is dependent on suppression of the maternal immune response and 
miscarriage may be a consequence of a failure of this suppression. It is assumed that both 
maternal and embryonic regulating factors protect the embryo against an adverse maternal 
immunological reaction. Maternal adaptation to the implanting embryo is needed for 
successful establishment of the foetal-placental unit, and the embryo must be able to 
stimulate an immunological reaction from the mother in order to become protected from 
 
 
Table 1. Causes of RM and their estimated frequencies in women with RM (Stephenson and Kutteh, 2007; 
Warren and Silver, 2008). 
 
Factor    Frequency 
Uterine defects ~15% 
 Anatomic deformation  
 Uterine fibroids  
 Cervical incompetence  
Endocrinologic ~10% 
 Abnormal hormone production  
 Diabetes  
 Thyroid dysfunction  
 Obesity  
Immunologic  ~15% 
 Aniphospholipid syndrome  
 Maternal autoimmune factors (acquired or inherited) 
Thrombophilic  ~10% 
 Prothrombotic state (acquired or inherited)  
Environmental  ~5% 
 Infections  
 Teratogens (alcohol, drugs, tobacco)  
Parental chromosome ~5% 
abnormality   
 Balanced translocations  
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cytotoxic molecules (Bulletti et al., 1996; Li et al., 2002b; Pandey et al., 2004). The 
mechanism by which the foetus escapes rejection by the maternal immune system is 
unknown. However, differences in the concentration of circulating immunocompetent 
cells, such as natural killer (NK) cells, and cytokines have been reported between RM 
women and controls (Wegmann et al., 1993; Reinhard et al., 1998; Ntrivalas et al., 2001; 
Yamada et al., 2001).  
 
Prothrombic state; A prothrombotic state can be broadly defined as any condition, 
whether inherited or acquired, that predisposes to venous or arterial thrombosis (Hiatt and 
Lentz et al., 2002). It is postulated that maternal thrombophilia is a risk factor for 
miscarriage because a successful pregnancy is dependent on satisfactory placental 
development and sustained placental function is based on placental circulation (Kujovich, 
2004). These processes require the establishment of an adequate foeto-maternal 
circulatory system, which in turn may be disturbed by a prothrombotic state. Factor V 
Leiden, mutations in the prothrombin gene, and protein C and protein S deficiencies are 
hereditary prothrombotic disorders of clinical importance and associations between 
increased risk of miscarriage and these thrombophilic disorders have been reported 
(Preston et al., 1996; Rey et al., 2003; Kujovich, 2004).  
 
One of the major acquired prothrombotic disorders is antiphospholipid antibody 
syndrome, in which the body recognizes its own phospholipids as foreign and produces 
antibodies against them. Lupus anticoagulant and anticardiolipin antibody are the two 
known antiphospholipid antibodies that are associated with RM (Levine et al., 2002). It is 
unknown exactly how the antiphospholipid antibody syndrome adversely affects 
pregnancy, but one theory is that it may cause blood clots in the blood vessels of the 
placenta, impairing placental function (Rand et al., 1997). However, antiphospholipid 
syndrome is a treatable cause of RM. Various treatments, such as heparin, aspirin, and 
intravenous immunoglobulin, have been used in attempts to improve the pregnancy 
outcome of women with antiphospholipid syndrome (Empson et al., 2002; Farquharson et 
al., 2002). Heparin is a thromboprophylactic agent that can bind to antiphospholipid 
antibodies, thereby protecting the trophoblast and maternal vascular endothelium from 
damage in early pregnancy. Later in pregnancy, when the intervillous circulation has been 
established, heparin helps to decrease the risk of placental thrombosis and infarction 
(Girardi, 2005, Bose et al., 2005). 
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Environmental factors; Heavy metals, organic solvents, and ionizing radiation are 
confirmed teratogens, and exposure to these can contribute to pregnancy loss (Dhont, 
2003). Alcohol and cocaine are also confirmed teratogens, while caffeine and smoking are 
suspected teratogens but their teratogenic impact is still controversial (Dominguez-Rojas 
et al., 1994; Parazzini et al., 1998; Cnattingius et al., 2000; Kesmodel et al., 2002).  
2.1.1 Risk factors for miscarriage 
In addition to identifiable causes of miscarriage, other factors increasing the risk for 
miscarriage have been reported. Increased maternal age is reported to be an independent 
risk factor for miscarriage (Risch et al., 1988; Abdalla et al., 1993; Nybo Andersen et al., 
2000). The risk of mscarriage increases rapidly after the age of 35. The
 
risk of a 
miscarriage is 9% in women aged 20-24 years, while in women aged over 45 years the 
risk is as high as 75% (Nybo Andersen et al., 2000). This is explained partly, but not 
totally, by the association of maternal age with increased likelihood of chromosomal 
abnormalities in the foetus (Munne et al., 1995; Snijders et al., 1999). 
 
The outcome of previous pregnancies, especially of the first pregnancy, is also an 
independent predictor of future pregnancy outcome. For young women who have never 
experienced pregnancy loss the rate of miscarriage is as low as 5% (Regan et al., 1989). 
The risk increases to approximately 30% for women with three or more losses but with a 
previous live-born infant, and up to 50% for women with no live-born infants (Poland et 
al., 1977), indicating that the risk of miscarriage increases with the number of previous 
miscarriages. Additionally, a normal karyotype in a pregnancy loss is a predictor of 
subsequent miscarriages because an abnormal foetal karyotype is associated with sporadic 
foetal loss. The frequency of abnormal foetal karyotypes significantly decreases with the 
number of miscarriages (Ogasawara et al., 2000).  
2.2 Genetic factors causing miscarriage 
In addition to the previously described identifiable causes of miscarriage, genetic factors 
are a major cause of clinically recognized miscarriages. In the following sections, the 
currently reported genetic causes associated with miscarriages are described. 
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2.2.1 Chromosomal abnormalities 
Most unbalanced chromosome aberrations result in severe phenotypes already in early 
pregnancy and therefore lead to miscarriage. Consequently the incidence of foetal 
unbalanced chromosomal abnormalities gradually decreases with duration of pregnancy to 
less than 1% among live-born children (Stern et al., 1996; Stephenson et al., 2002). 
Overall, 50-70% of all sporadic miscarriages are associated with cytogenetic abnormalities 
in the foetus. The most frequent of these abnormalities is trisomy, followed by polyploidy, 
monosomy X, and unbalanced translocation (Kalousek et al., 1993; Stephenson et al., 
2002). The most common trisomy is trisomy of chromosome 16, followed by trisomy of 
chromosomes 21 and 22 (Stephenson and Kutteh, 2007). These chromosomal 
abnormalities may be inherited or may arise de novo in the germ cells due to
 
aberrant 
oocyte spindle formation and meiotic division (Devine et al., 2000; Kuo, 2002).  
 
 In women with RM the rate of chromosomal abnormalities in the foetus is lower than 
in women with sporadic miscarriage. The miscarriages in women with RM may be due to 
de novo numerical chromosome abnormalities, in particular autosomal trisomies of 
chromosomes 13, 14, 15, 16, 21, and 22, and monosomy X (Pandey et al., 2005; Warren 
and Silver, 2008). In women with RM, however, the miscarriage may also be due to 
recurrent chromosomal anomalies in the foetus resulting from a balanced aberration in one 
of the parents inherited by the offspring in an unbalanced form. Cytogenetic screening of 
couples with RM has revealed that parental chromosomal abnormalities occur in either 
partner in 5-7% of couples with RM, while the rate in the normal population is 
approximately 0.2% (Fryns and Buggenhout, 1998). Balanced translocations in either 
parent, including reciprocal and Robertsonian translocations, are the most common 
abnormalities, detected in about 4% of couples with RM. The other chromosomal 
abnormalities include inversions and sex chromosome abnormalities (Tulppala et al., 
1993; Clifford et al., 1994; Fryns and Buggenhout, 1998). Even though the theoretical risk 
for abnormal offspring for phenotypically normal carriers of balanced translocations is 
approximately 50%, preimplantation genetic diagnosis (PGD)  analysis has shown that the 
risk varies greatly. For carriers of a balanced translocation the risk of conceiving a 
chromosomally abnormal embryo, due to abnormal segregation at meiosis, varies from 20-
80%. The reproductive risk conferred by chromosome rearrangements is dependent on the 
size, location, and type of rearrangement and whether it is carried by the woman or her 
male partner (Munne et al., 2000; Otani et al., 2006; Lim C et al., 2008).  
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2.2.2 Skewed X chromosome inactivation 
X chromosome inactivation (XCI) is defined as the process where one of the two X 
chromosomes in each somatic cell of a healthy female is inactivated during early 
embryogenesis. The process is important to achieve appropriate dosage compensation for 
X chromosomal genes (Lyon, 1961; Brown and Robinson, 2000). Females are therefore 
mosaics for two
 
cell types; cells with the paternal X chromosome as the active
 
X and cells 
with the maternal X chromosome as the
 
active X. Normally the process occurs randomly 
on both the maternal and paternal X chromosome, resulting in a 50:50 distribution
 
of the 
two cell types. A significant deviation from this distribution is called skewed XCI (Puck 
and Willard, 1998; Minks et al., 2008). Recently, several studies have shown that women 
experiencing RM exhibit nonrandom XCI more often than control women (Lanasa et al., 
1999; Uehara et al., 2001; Kuo et al., 2008). Kuo et al. (2008) reported extremely skewed 
XCI in 7.7% of RM women and in 1.3% of control women (p=0.01). 
 
Skewed XCI, defined as preferential inactivation of one of the two X chromosomes, 
may be the result of a chance event, or due to genetic factors involved in
 
the X inactivation 
process (Brown and Robinson, 2000). In some cases a non-random inactivation pattern 
may be an indicator of an abnormality in the inactivated X, e.g. X chromosome 
aberrations such as microdeletions or mutations in X chromosomal genes (Belmont, 1996; 
Uehara et al., 2001). Deviation from random inactivation rates can also lead to the 
expression of recessive X-linked traits in heterozygous females, who are expected to be 
healthy carriers of the disease gene (Azofeifa et al., 1995). It has been proposed that X-
linked mutations which are lethal in males cause skewed XCI in female carriers. For 
example, microphthalmia with linear skin defects syndrome (MLS) and oral-facial-digital 
syndrome type 1 (OFD1) are previously described X-linked dominant male-lethal diseases 
(Franco and Ballabio, 2006). Such mutations may result in loss of male conceptuses and 
increased frequency of miscarriage in carrier females (Lanasa et al., 1999; Uehara et al., 
2001).  
2.2.3 Y chromosome microdeletions 
The majority of the testing for RM assesses the woman. The male partners, however, have 
been less thoroughly investigated. Semen analysis is not generally included in the initial 
assessment for RM. Yet, sperm integrity is required for sperm–egg interactions, 
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fertilization, and early embryonic development and sperm quality is associated with the 
embryo’s ability to reach the blastocyst stage and progress to implantation (Simerly et al., 
1995; Van Blerkom, 1996; Moomjy et al., 1999). 
 
Microdeletions of the long arm of the human Y chromosome are associated with 
variable spermatogenic failure (Vogt et al., 1996; Hopps et al., 2003). These 
microdeletions occur in regions called AZFa, AZFb, and AZFc (more recently named 
AZFa, P5/Proximal-P1, P5/Distal-P1, P4/Distal-P1, b2/b4-AZFc), containing a number of 
genes (Hopps et al., 2003; Ferlin et al., 2007). Although ten recurrent deletions in the AZF 
regions have been described in detail (Ferlin et al., 2007), surprisingly little is known 
about the function of the individual genes and transcription units located within these 
regions (Hopps et al., 2003; Foresta et al., 2005). Y chromosome microdeletions are found 
in approximately 7% of men with very low sperm counts (Ferlin et al., 2007). These men 
also often show a higher incidence of sperm chromosomal abnormalities (Foresta et al., 
2005). An elevated rate of sperm chromosome abnormalities has also been found in some 
men of RM couples (Rubio et al., 1999; Egozcue et al., 2000). A recent study reports that 
the incidence of sperm chromosome abnormalities is 16.5% in male partners of women 
with RM, while the incidence is under 5% in controls  (Al-Hassan et al., 2005). 
Interestingly, a pilot study conducted to determine if Y chromosome microdeletions are 
associated with RM, reported that a significant portion (82%) of male partners of women 
with RM had Y chromosomal microdeletions, which may underlie the miscarriages 
experienced by their partners (Dewan et al., 2006). 
2.3.4 Gene mutations and polymorphisms 
Mutations and polymorphisms in several genes are suggested to contribute to RM. Many 
of these sequence variations are located in genes involved in immunological mechanisms 
or blood coagulation pathways, but also genes involved in other functions have been 
associated with RM.  
 
Since the conceptus displays paternal gene products and antigens, it is possible that the 
maternal
 
immune system recognizes these as foreign, resulting in an immune response 
(Dalton et al., 1998; Hill and Choi, 2000). In recent years, several genes involved in the 
immune response have been associated with pregnancy loss. The CTL-A gene is a 
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regulator of T-cell activation and an A/G polymorphism in exon 1 of the gene has been 
reported to be associated with RM in the Chinese population. The frequency of the GG 
genotype in RM patients was significantly higher compared with controls (48.8% versus 
33.3%, p = 0.011) (Wang et al., 2005). Polymorphisms in the major histocompatibility 
complex have also been associated with RM. A polymorphism in the HLA-G promoter 
region, the HLA-G *0104 and *0105N alleles (Aldrich et al., 2001; Ober et al., 2003) and 
the HLA-DRB1 *1505 allele have been associated with the immunopathogenesis of RM 
(Takakuwa et al., 2003). In addition, a number of cytokine gene polymorphisms are 
associated with pregnancy loss. Cytokines are critical immunoregulatory molecules which 
play a crucial role in early embryo development and placentation. Associations have been 
shown between IL-6, IL-10, and IFN-γ gene polymorphisms and RM (Daher et al., 2003; 
Costeas et al., 2004; Prigoshin et al., 2004; von Linsingen et al., 2005). 
 
It is assumed that maternal thrombophilia is a risk factor for miscarriage because a 
successful pregnancy is dependent on an adequate foeto-maternal circulatory system, 
satisfactory placental development and sustained placental function. These functions may 
be disturbed by a prothrombotic state. Factor V and prothrombin gene mutations, protein 
C and protein S deficiencies, cause hereditary prothrombotic disorders (Preston et al., 
1996; Kujovich, 2004). Associations between these thrombophilic disorders and an 
increased risk of miscarriage have been reported. Depending on the study the Factor V 
Leiden mutation and the prothrombin G20210A mutation are reported to increase the risk 
for RM between 2-fold and 5.5-fold, and between 2.5-fold and 4.9-fold, respectively 
(Souza et al., 1999; Foka et al., 2000; Reznikoff-Etiévan et al., 2001; Rey et al., 2003). 
Protein C and protein S deficiencies are much rarer and they have been reported to 
increase the risk of early RM ~3.5-fold and ~14.5-fold, respectively (Rey et al., 2003; 
Kujovich, 2004). The MTHFR gene has an important role in homocysteine metabolism 
and missense mutations C677T and A1298C are known to cause hyperhomocysteinemia. 
Hyperhomocysteinemia is a risk factor for vascular thrombophilia and has also been 
shown to associate with RM (Couto et al., 2005; Mtiraoui et al., 2006). In addition, 
polymorphisms in the ITGB3 gene, which encodes a human platelet antigen, may increase 
the risk of miscarriage by causing thrombophilia. The PLA2 polymorphism in the ITGB3 
gene was shown to increase the risk of foetal loss 3.6-fold (Ruzzi et al., 2005).  
 
In addition, various other genes have been associated with pregnancy loss. For 
example, mutations in the SCO2 gene, needed for cytochrome c oxidase assembly, were 
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detected in a compound heterozygous state in aborted foetuses and are suggested to cause 
miscarriage (Tay et al., 2004). A novel A/G polymorphism in intron 6 of the eNOS gene, 
which is active during implantation, was recently reported to be associated with RM 
(Suryanarayana et al., 2006). A polymorphism in the VEGF gene, a well characterized 
regulator of angiogenesis, was also recently reported as a new susceptibility factor for 
RM. Homozygosity of the VEGF –1154A variation was more frequent in RM women 
compared to controls and increased the risk of RM 2.7-fold (Coulam and Jeyendran, 
2008). 
2.2.5 Aberrant placental gene expression  
The growth and differentiation of placental structures are regulated by many genes and the 
placenta is very sensitive to genetic disruption, as reflected by the increasing list of 
targeted mouse mutations in genes such as Mash2 and Hand1 that cause placental defects 
and embryonic lethality (Rossant and Cross, 2001). Genetic abnormalities that affect the 
development of the placenta can cause placental insufficiency, foetal growth retardation 
and embryonic death, both in mice and humans (Rossant and Cross, 2001; Cross, 2006). 
 
It is assumed that normal placentation and normal placental functions are mediated by 
differential
 
gene expression in the placenta. It has also been suggested that genes 
expressed in the chorionic villi act as critical regulators of placentation and hence of early 
human development (Dizon-Townson et al., 2000; Baek, 2004). Recently, over 30 genes 
that are expressed
 
aberrantly in pregnancy failure have been identified. The genes showing 
different levels of expression
 
between controls and patients with RM can be mainly 
grouped as
 
immunity related, angiogenesis related, and apoptosis related genes (Baek et 
al., 2002; Choi et al., 2003). Higher
 
expression levels of apoptosis related genes such as 
caspase
 
3, 6, 7, 8, 9, 10, 12, BAD, BAX, BID, Fas and FasL were shown
 
in chorionic villi 
from patients with RM compared to controls (Choi et al, 2003). Immunity related genes 
with aberrant gene expression in chorionic villi include PP14, MUC1 (Baek et al., 2002), 
CD95 (Hoshimoto et al., 2002), and Annexin II (Aarli et al., 1997). These genes may be 
involved in immunological foeto-maternal reactions. Fibronectin, Integrin and VEGF are 
examples of angiogenesis related genes showing aberrant gene expression in RM placenta 
(Choi et al, 2003). These genes are involved in the formation of blood vessels that are 
crucial for placental and embryonic development. 
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2.2.6 Epigenetic mechanisms  
The term epigenetics refers
 
to processes that regulate gene activity without affecting
 
the 
DNA sequence and are heritable through cell division. Epigenetic modifications of DNA 
such as methylation are important for genome function during development, and 
disturbances in the highly coordinated epigenetic processes contribute to developmental 
failures (Lucifero et al., 2004; Santos and Dean, 2004). In most mammalian species, 
including humans, there are at least two developmental periods during which methylation 
patterns are reprogrammed genome wide; germ cell development and preimplantation. 
After genome wide demethylation of the genome in developing germ cells, remethylation, 
which resets the parent-of-origin specific marks, occurs. The second phase of 
reprogramming of methylation occurs during the preimplantation stage. The paternal 
genome is actively demethylated within a few hours of fertilization in the human zygote, 
whereas the maternal genome is passively demethylated by a replication dependent 
mechanism after the two cell embryo stage. After the demethylation stage, de novo 
methylation of the genome occurs in the developing embryo. This reprogramming is likely 
to have a crucial role in establishing nuclear totipotency required for normal development 
(Reik et al., 2001; Reik and Dean, 2001; Haaf, 2006). 
 
Genomic imprinting is a mechanism which results in differential expression of 
maternal and paternal genes. Only one of the inherited
 
gene copies is active in an embryo 
depending on the parental origin of the gene. DNA methylation in germ cells is critical for 
imprinting as most imprinted genes have differentially methylated regions (Reik and 
Dean, 2001; Swales and Spears, 2005). Anomalous expression of imprinted genes during 
development is sometimes caused by imbalanced representation of maternal and paternal 
genetic contributions, uniparental disomy, and is associated with developmental delay or 
gestational loss (Mutter, 1997).  
 
It is estimated that there are several hundred imprinted genes in
 
the human genome. It 
has been
 
argued that imprinted genes play essential roles in controlling
 
the placental 
supply of maternal nutrients to the foetus, by
 
regulating the growth of the placenta and/or 
the activity of
 
transplacental transport systems. In some cases,
 
errors in genomic 
imprinting are embryo lethal while in others
 
they lead to developmental disorders and 
diseases (Reik and Dean, 2001; Lucifero et al., 2004; Swales and Spears, 2005).  
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3 Identification of genetic causes underlying RM 
Despite numerous investigation the cause of miscarriage remains unknown in 
approximately 50% of cases (Plouffe et al., 1992; Tulppala et., al 1993, Clifford et al., 
1994). A number of possible aetiologies have been proposed to explain the RM in these 
cases. The hypotheses, however, change over time and new findings have enriched our 
understanding of possible mechanisms underlying RM. For example, specific HLA-G 
alleles (Aldrich et al., 2001) and skewed X-inactivation (Lanasa et al., 1999; Uehara et al., 
2001) are newly factors identified to be associated with RM and could, in some cases, be 
the cause for unexplained RM. However, additional genetic factors contributing to the 
aetiology of RM are likely to be detected.  
 
There are different mechanisms by which genetic factors may contribute to 
miscarriage, and different modes of inheritance by which these mutations and 
polymorphisms are transmitted from parents to foetus. Dominant de novo mutations 
arising in the germ cells of the parents may result in affected foetuses and cause 
miscarriage. Alternatively, de novo mutations during an early developmental stage in the 
foetus may result in mosaicism, which also may cause a severe phenotype resulting in 
miscarriage (McFadden and Friedman, 1997; Los et al., 2004). De novo mutations are 
difficult to study because these mutations cannot be detected by studying DNA samples 
from parents and foetal/placental samples are rarely available.  
 
Autosomal recessive mutations cause a number of genetic diseases, and are common 
especially in isolated populations (Peltonen et al., 1999; Norio, 2003a; Teebi and Teebi, 
2005; Weinstein, 2007). The role of recessive mutations in specific genes in RM can be 
studied without foetal samples by screening the parents for heterozygous mutations, which 
when inherited by the foetus in a homozygous state are expected to be lethal. In isolated 
populations disease causing mutations are often enriched and may also show uneven 
geographical distribution. Evidence of such geographical clustering can be studied using 
genealogic data (Kere, 2001; Norio, 2003a).  
 
Not only autosomal mutations, but also abnormalities in the sex chromosomes can 
underlie RM. X-linked mutations are predicted to be capable of inducing foetal loss. Some 
X-linked recessive mutations are expected to be lethal to all male foetuses inheriting the 
mutation and thereby result in miscarriage (Lanasa et al., 1999). Recently, a study 
  
 
 
27 
suggested an association between Y-chromosome microdeletions and RM (Dewan et al., 
2006). The role of these genetic factors in the aetiology of RM can be further studied 
using parental DNA samples. 
 
In addition to the nuclear genome, the mitochondria contain their own DNA, which is 
transmitted only from the mother to the foetus. The human mitochondrial genome is 
16,569 bp in size and encodes 37 genes (DiMauro, 2001). Mutations in these genes 
leading to dysfunctional proteins may have a role in RM as the mitochondria are involved 
in processes necessary for early development (Van Blerkom, 2004).  
 
It is also possible that mutations in imprinted genes can cause miscarriage. When the 
imprinting mechanism is malfunctioning loss of function or inappropriate expression can 
occur in intact genes and may result in miscarriage (Reik and Dean, 2001; Swales and 
Spears, 2005). The role of imprinted genes in RM is, however, difficult to study as 
imprinting still is a poorly understood phenomenon.  
 
Recently, several genes such as CTL-A, IL6, ITGB3, and VEGF have been shown to be 
associated with RM (Wang et al., 2005; von Linsingen et al., 2005; Ruzzi et al., 2005; 
Coulam and Jeyendran, 2008) and it is likely that other genes, in which mutations and 
polymorphisms cause or increase the risk for miscarriage, will be identified in the near 
future. Therefore, further studies and screening of candidate genes are required to establish 
the role of genetic factors in RM. 
3.1 Identification of disease genes  
3.1.1 The Human Genome Project 
The human genome consists of approximately 3 billion base pairs (bp) and is estimated to 
contain 20 000-25 000 genes (Balakrishnan et al., 2005; Antonarakis and Beckmann, 
2006). The Human Genome Project (HGP) began in 1990 and its main goals were to 
determine the nucleotide sequence of the human genome and to identify all human genes. 
A draft sequence of the human genome was published in 2001 (Lander et al., 2001; Venter 
et al., 2001). An updated sequence, published in 2003, covered ~99% of the euchromatic 
genome (International Human Genome Sequencing Consortium 2004). The first complete 
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genome sequence of a single human individual was published in 2007 (Levy et al. 2007). 
In addition to the human genome, the genoms of hundreds of other organisms have been 
sequenced (www.ebi.ac.uk/genomes/index.html). This genomic information has 
dramatically changed the process of identifying disease genes. It provides new, invaluable 
tools for understanding the basic human genetic make-up and how variations in the 
genomic sequence result in disease (Peltonen and McKusick, 2001; 
http://genomics.energy.gov). 
3.1.2 Traditional identification of disease genes 
Before the complete human genome sequence was available, disease genes were 
traditionally identified using functional and positional cloning methods. In functional 
cloning the gene is isolated based on information regarding the protein or its function. The 
method can be used if the amino acid sequence of a protein is at least partially known 
(Collins, 1992). However, most often, the protein encoded by the disease gene is not 
known and the positional cloning method is used to identify a gene based on the 
knowledge about its physical location in the genome. Using polymorphic markers and 
DNA samples from families with affected members the disease gene locus is localized to a 
genomic region by linkage analysis. Disease gene identification based on positional 
cloning has been widely used in the research of monogenic diseases (Collins, 1992; 
Collins, 1995).  
3.1.3 The candidate gene approach 
The candidate gene approach is an important step towards disease gene identification and 
relies on information about known genes. New effective methods for mutation screening 
together with the information offered by the HGP have made the candidate gene approach 
a commonly used method to search for disease genes as information on physical locations 
and sequences of many genes is available. The candidate gene approach can be used when 
the biochemical background of the defect of interest is known, when a chromosomal 
region has been linked to a disease or if an animal model of a disease has been established 
(Collins, 1992; Ballabio, 1993; Zhu and Zhao, 2007). The mouse is a widely used model 
organism for studying mammalian gene function and genes causing a phenotype in the 
mouse can be used as candidate genes in human disease studies (Strachan and Read, 
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2004). Interaction partners of identified proteins defective in a disease can also be 
considered as candidate genes for the disease of interest. In addition, candidate genes can 
be selected based on results from genome wide expression profiling data showing 
differences in gene expression between cells or tissues from affected and control 
individuals (Antonarakis and Beckmann, 2006). 
3.1.4 Mutation screening 
When a candidate gene is selected, the next step in disease gene identification is searching 
for mutations in the gene under study. During the past years several different methods 
have been used for mutation screening. To date, one of the most commonly used method 
is direct sequencing. In addition, denaturing high-performance liquid chromatography 
(dHPLC) (Xiao and Oefner 2001) and multiplex ligation-dependent probe amplification 
(MLPA) (den Dunnen and White, 2006) are frequently used to screen DNA samples for 
sequence variations due to their sensitivity and specificity. A set of patients and control 
DNA samples are screened for mutations segregating with the disease phenotype. It is 
important to screen a set of healthy control individuals to be able to assess the significance 
of the nucleotide changes and to confirm that the variation truly is associated with the 
disease (Strachan and Read, 2004).  
 
When screening candidate genes different types of sequence variations can be 
identified. Nonsense mutations are point mutations that introduce premature stop codons 
into the coding regions. Nonsense mutations usually lead to the degradation of the 
transcript or may produce truncated nonfunctional protein products. Missense mutations 
are point mutations that result in the substitution of an amino acid and are sometimes 
difficult to differentiate from rare neutral polymorphisms. A missense mutation is more 
likely to be pathogenic if it changes an amino acid that is conserved. If the change alters 
the chemical nature of the side chain of the amino acid this usually suggests a pathogenic 
role for the variation. In addition, sequence variations in parts of the gene that code for  
functionally important domains are more likely to be pathogenic. Deletions, insertions, 
and duplications can disrupt the reading frame, resulting in a completely different protein 
translation. In addition to frameshift mutations, deletions, insertions, and duplications 
can introduce premature stop codons or alter the protein by amino acid(s) deletion or 
insertion (Strachan and Read, 2004).  
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Splicing mutations affect the consensus sequences at splice donor, splice acceptor, or 
splice branch sites and may abolish the splicing partially or completely. In addition, 
cryptic splice sites can be activated or splicing enhancers and silencers altered. These 
types of splicing mutations may lead to complete or partial exon skipping or intron 
retention (Cartegni et al. 2003; Baralle and Baralle, 2005). In addition, neutral and silent 
mutations/polymorphisms are likely to be observed in candidate gene screening. A 
neutral mutation is a variation that results in the substitution of a different, but 
chemically similar amino acid. Silent mutations are variations that do not result in a 
change to the amino acid sequence. They may occur either within an exon or within the 
non-coding regions of the gene (Strachan and Read, 2004). Polymorphisms in the non-
coding regions of the genome, including the promoter region, the 5´- and 3´-untranslated 
regions, and the intragenic regions are also commonly detected. Some of these variations 
may affect gene splicing, and transcription and translation, and thereby the expression of 
the gene (Wang et al., 2006). 
3.1.5 Confirming the nature of a new genetic variation 
Identifying a disease gene is a possible starting point to study the function of the protein 
encoded by the gene. A candidate disease gene has to be carefully studied to determine if 
there is enough evidence that the identified changes are not just neutral polymorphisms 
but do cause the disease under study. The candidate gene can be demonstrated to be the 
disease gene in different ways. Mutation screening is usually the first step in the process. 
Identification of mutations in several unrelated individuals strongly suggests that the 
candidate gene is causing the disease, but formal proof requires additional evidence. To 
prove that the candidate gene has a pathogenic role in the disease functional studies, such 
as restoration of the normal phenotype in vitro, or production of an animal model for the 
disease, are required (Strachan and Read, 2004).  
3.2 Mouse as a model organism 
Genetic approaches in model organisms provide a powerful means by which to examine 
the biological basis of human diseases. Over the past century, the mouse has become the 
most used animal model system for genetic research because of its close genetic and 
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physiological similarities to humans. In addition, its small size and short generation time 
have allowed large scale mutagenesis experiments and extensive genetic crosses. Many 
mouse mutations have been established as reliable models of human disease while others 
have provided insight into complex developmental and physiological pathways in 
mammals. Targeted mutagenesis approaches in the mouse have led to dramatic increases 
in our understanding of human disease processes (Brown, 1998;  Brown and Nolan, 1998; 
Nolan et al., 2002). There are a number of mouse models described in the literature and 
databases on different mutant strains are available on the internet 
(http://ceolas.org/VL/mo/; Peters et al., 2007).  
 
Sequencing of the mouse genome was initiated in 1999 and the first draft sequence 
was published in 2002 by Waterston and coworkers. Because of the comparatively high 
level of sequence conservation between human and mouse coding sequences, almost all 
human genes have an easily identifiable mouse homolog. Therefore, disease genes 
identified in mouse models are usually good candidate genes for human diseases. The 
mouse and human genomes both appear to contain 20 000-25 000 protein coding genes 
and more than 90% of the mouse genome can be aligned with a region of the human 
genome due to conserved synteny (Waterston et al., 2002). In addition to providing 
important data on mouse genes and the structure of the mouse genome, the sequence data 
have also been valuable in comparative genomics. One application of human-mouse 
comparative sequence analysis involves the identification of orthologous genes. 
Functionally important genomic regions are commonly homologous in human and mouse 
genomes and genetic information obtained from the mouse can thereby be used for human 
disease studies (Collins et al., 1998; Nobrega and Pennacchio, 2004).  
 
Apart from the very early stages of preimplantation development, human embryos are 
inaccessible for research and studies are limited to diseased aborted foetuses. Due to the 
difficulties of studying implantation and foetal development in humans, much of our 
knowledge of the genes involved in these processes has been derived from animal models. 
There are several animal models used to gain information about human development 
including; nematode worm, fruit fly, rat, guinea pig, rabbit, pig, sheep, cow, and non-
human primates (Lee and DeMayo, 2004; Dvash et al., 2006; Carter, 2007). The most 
commonly used model organism is the mouse, but there are, however, significant 
differences in the mode of implantation, placental structure, yolk sac, number and function 
of placental hormones, and particularly in the length of pregnancy between mouse and 
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human (Rossant and Cross, 2001; Carter, 2007). Despite these differences, gene ablation
 
in the mouse has proven to be a powerful tool in elucidating
 
gene function during 
embryonic development (Rossant and Cross, 2001; Dvash et al., 2006).  
 
Knock-out mouse models have been used to identify a number of genes required for  
normal implantation and placentation (Rossant and Cross, 2001;Lee and DeMayo, 2004; 
Carter, 2007). In addition, imprinted genes required for normal embryo development have 
been studied in mouse models (Mutter, 1997; Lucifero et al., 2004). A number of mouse 
models, in which deletions of a specific gene are embryo-lethal at a specific 
developmental stage, have also been described (Healy et al., 1995; Sah et al., 1995; Wang 
et al., 1996; Gu et al., 2002). These mouse models can be used to identify candidate genes 
for human RM. A gene identified in mouse to be embryo lethal can be considered as a 
clinically important candidate gene for human RM if the mouse and human genes have a 
highly homologous sequence and similar normal functions in both species.  
3.3 Candidate genes for RM 
The following sections describe four candidate genes for human RM. They were selected 
based on results from studies on animal models. In addition, the genes encoded by the 
mitochondrial genome were considered as candidate genes because the mitochondria are 
involved in processes important for development but their role in early development is still 
unknown.  
3.3.1 Amnionless   
The amnionless mouse model 
The amnionless mouse has a recessive prenatally lethal insertional mutation in the Amn 
gene (Wang et al., 1996). The gene was named Amnionless (Amn) as the first visibly 
striking feature of the mutant mouse was the lack of an amnion surrounding the foetus. 
Examination of the mutant embryos at different times of gestation indicated that the 
mutation causes a gastrulation stage (embryonic day (E) 6.5-E8.0) defect in the 
homozygous mutant mouse (Wang et al., 1996; Tomihara-Newberger et al., 1998). 
Although gastrulation begins normally in the Amn mutants they remain small and 
undifferentiated and generate no amnion. The growth and differentiation of the embryonic 
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ectoderm cells are severely impaired in the mutant embryos. The first signs of abnormal 
development in embryos homozygous for the transgene insertion can be seen between 
E6.5 and E7.0 and the mutant embryos die and are resorbed between E9.5 and E10.5 
(Table 2) (Wang et al., 1996).  
 
Functions of the Amn gene 
The Amn gene encodes a type I transmembrane protein (Kalantry et al., 2001). During the 
early
 
post-implantation stages mouse Amn is expressed exclusively in the visceral 
endoderm (Tomihara-Newberger et al., 1998; Kalantry et al., 2001). In adults, both mouse 
and human Amn is expressed mainly
 
in the kidney and the intestinal epithelium (Tanner et 
al., 2003; Strope et al., 2004).  
 
The exact role of the Amn protein in mouse development has not yet been determined, 
but the gene function is required in the visceral endoderm for normal primitive streak 
formation (Tomihara-Newberger et al., 1998). The visceral
 
endoderm is an epithelial cell 
layer that does
 
not contribute directly to the foetus, but is needed to absorb
 
and digest 
nutrients from the maternal environment, to provide signals required for the organization 
of
  
the body axes, and to secrete factors that promote correct positioning of the
 
primitive 
streak (Beddington and Robertson, 1999; Martinez-Barbera
 
and Beddington, 2001; Perea-
Gomez et al., 2002). At the onset of gastrulation the middle region of the primitive streak 
is absent in the Amn mutant mouse (Tomihara-Newberger et al., 1998).  
 
In wild-type mouse embryos Amn co-localizes with two other gene products,
 
cubilin 
(Cubn) and megalin, at the surface of the visceral endoderm. In the Amn mutant mouse 
Cubn fails to localize to the surface of the visceral endoderm. This indicates that Amn is 
an essential component of
 
the Cubn receptor complex, and it has been suggested that the 
Amn/Cubn-complex
 
is required for endocytosis/transcytosis of one or more ligands
 
in the 
visceral endoderm. (Strope et al., 2004). In humans, AMN and CUBN also form a 
complex. This complex is required for uptake of vitamin B12 (Fyfe et al., 2004; Luder et 
al., 2008). Mutations in either of these genes cause selective intestinal malabsorption of 
vitamin B12, a rare autosomal recessive disorder known as Imerslund-Gräsbeck syndrome 
(IGS) or megaloblastic anemia 1 (Imerslund, 1960; Gräsbeck et al,. 1960; Aminoff et al., 
1999; Tanner et al., 2004).  
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The fact that the Amn protein has a similar structure in both mice and humans suggests 
similar functions in both species, making Amn a candidate gene for miscarriages in 
humans. Amn may be required in the extra-embryonic endoderm during early embryonic 
development, and in the intestine for the uptake of vitamin B12 in adults in both species. 
 
 
 
Table 2. Comparison between mouse and human stages of early development and the timepoints at which 
TM, AMN, and EPCR mutant mice embryos die. The carnegie stages (CS) provide a universal system for 
staging and comparing the embryonic development of vertebrates. The stages are based on the external and 
internal morphological development of the embryo, and are not directly dependent on either age or size. The 
stages covers approximately the first 60 days of human development and nearly the entire intrauterine 
development of mouse (UNSW Embryology, http://embryology.med.unsw.edu.au/embryo.htm) The table 
shows the age of human and mouse embryos in days at specific stages. Implantation takes place during CS 
5, gastrulation starts during CS 7, neurogenesis starts during CS 8, and heart beats can be detected at CS 10.  
 
        Developmental stages at 
 Carnegie stage  Human Age  Mouse Age     lethality of mutations 
CS 1 E 1 E 0.5   
CS 2 E 2-3 E 1-2   
CS 3 E 4 E 3   
CS 4 E 5-6 E 4   
CS 5 E 7-12 E 5-6 Implantation 
CS 6 E 13-15 E 6.5   
CS 7 E 15-17 E 7 Gastrulation 
CS 8 E 17-19 E 7.5 Neurogenesis 
CS 9 E 19-21 E 8   
CS 10 E 22-23 E 8.5 Heart beats 
CS 11 E 23-26 E 9 TM mutants die 
CS 12 E 26-30 E 9.5   
CS 13 E 28-32 E 10 AMN mutants die 
CS 14 E 31-35 E 10.5 EPCR mutants die 
CS 15 E 35-38 E 11   
CS 16 E 37-42 E 11.5   
CS 17 E 42-44 E 12   
CS 18 E 44-48 E 13   
CS 19 E 48-51 E 13.5   
CS 20 E 51-53 E 14.5   
CS 21 E 53-54 E 15   
CS 22 E 54-56 E 15.5   
CS 23 E 56-60 E 16   
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3.3.2 Thrombomodulin and Endothelial Protein C Receptor 
The Thrombomodulin mouse model 
In mice, absence of the blood-clotting regulator thrombomodulin (TM) causes embryonic 
lethality before development of a functional cardiovascular system (Healy et al., 1995). 
TM has been shown to have a dual role in development as TM is needed in two distinct 
tissues. Expression of TM in non-endothelial cells of the placenta is required for proper 
function of the early placenta, while the absence of TM from blood vessel endothelium 
causes excessive activation of the embryonic blood coagulation system (Healy et al., 1995; 
Isermann et al., 2001). The first indications of abnormal development are observed at E8.5 
in homozygous TM-deficient (TM-/-) embryos and manifest as overall growth retardation. 
This initial phenotype is invariably followed by rapid and complete resorption of 
homozygous TM-null embryos within the next 10-12 hours (Table 2) (Healy et al., 1995; 
Isermann et al., 2001).  
 
 
Functions of the TM gene 
TM is an endothelial cell surface glycoprotein expressed on the endothelium of arteries, 
veins, capillaries, lymphatics, and on trophoblast cells of the placenta (Maruyama et al., 
1985; Weiler-Guettler et al., 1996; Fazel et al., 1998). TM plays a key role in the protein C 
anticoagulant pathway, which is a major regulatory system providing an inhibitory 
feedback mechanism that suppresses blood coagulation by preventing fibrin formation.  
TM inhibits blood coagulation by forming a 1:1 complex with thrombin. Binding of 
thrombin to this high-affinity receptor alters its specificity toward several substrates. The 
complex converts protein C into the natural anticoagulant activated protein C (APC) 
approximately 1000 times faster than thrombin alone. APC proteolytically inhibits the 
coagulation cofactors Va and VIIIa, resulting in down-regulation of the activity of the 
coagulation system (Figure 3) (Maruyama et al., 1985; Van de Wouwer et al., 2004; 
Dahlbäck and Villoutreix, 2005). 
 
A number of polymorphisms in the TM gene have been characterized and their 
association with thrombosis or arteriosclerosis are subjects of ongoing research. These 
associations have been evaluated in several studies and the results suggest that the 
relevance of TM mutations in these complications is small or limited to a small subgroup 
of individuals (Ireland et al., 1997; Doggen et al., 1998; Le Flem et al., 1999; Nakazawa et 
al., 2002). The most convincing evidence that reduced TM function causes thrombosis is 
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derived from animal studies. In the past three genetically engineered mouse lines with 
various degrees of TM dysfunction have been generated, showing different degrees of 
thrombosis (Healy et al., 1995; Healy et al., 1998; Isermann et al., 2001). It appears that 
mutations causing a substantial reduction of TM function are very rare in humans (Faioni 
et al., 2002), possibly because such loss-of-function mutations would lead to foetal loss at 
an early developmental stage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The protein C anticoagulant pathway. 1) Activation of prothrombin (PT); the Xa-Va complex 
converts prothrombin to thrombin (T), which forms a complex with TM. 2) Protein C activation; protein C 
(PC) binds to EPCR, which presents PC to the T-TM complex. 3) Cofactor inactivation; activated protein C 
(APC) binds protein S (PS). This complex inactivates factors Va and VIII thereby preventing blood 
coagulation.  
 
 
The EPCR mouse model 
Deletion of the endothelial protein C receptor (EPCR) gene in mice leads to embryonic 
lethality. Genotyping of progeny obtained from EPCR+/  interbreeding indicates that 
EPCR /  embryos die on or before E10.5 (Table 2).  However, EPCR /  embryos 
removed from extra-embryonic membranes and tissues at E7.5 and cultured in vitro 
develop beyond E10.5, suggesting a role for EPCR in the normal function of the placenta 
and/or at the maternal-embryonic interface (Gu et al., 2002). EPCR is normally detected 
on giant trophoblast cells, which are in direct contact with the maternal circulation and its 
clotting factors. In the giant trophoblast cells derived from EPCR /  embryos thrombosis 
is observed (Li et al., 2005). These observations provide evidence that extraembryonic 
EPCR expression is essential for embryonic viability and plays a critical role in the control 
of blood coagulation at the foeto-maternal boundary (Gu et al., 2002).  
 
   TM 
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Functions of the EPCR gene 
EPCR is a type 1 transmembrane protein and is strongly expressed in the endothelial cells 
of arteries and veins in heart and lung, and less intensely expressed in capillaries in the 
lung and skin (Laszik et al., 1997; Simmonds and Lane, 1999; Esmon, 2000). It is also 
expressed in the placenta and the developing cardiovascular system of the foetus (Crawley 
et al., 2002). EPCR is seen as a complementary cofactor in protein C activation (Figure 3). 
It binds
 
both protein C and APC with similar affinity and functions in the protein C 
pathway by binding protein C and presenting it to the TM-thrombin complex on the 
endothelium, thereby further enhancing the rate of protein C activation and suppressing 
blood coagulation (Stearns-Kurosawa et al., 1996; Van de Wouwer et al., 2004).  
 
In human, sequence variations in the EPCR gene are associated with the risk of 
thrombosis. A heterozygous mutation in EPCR has been identified in humans who 
develop thrombosis and myocardial infarction. This mutation, c.323-9_336dup, is a 23-bp 
insertion that leads to the formation of a truncated receptor that lacks the extracellular and 
transmembrane domains and is unable to sustain protein C activation (Biguzzi et al., 
2001). However, a common polymorphism in EPCR, c.717+16G>C, seems to reduce the 
risk of thrombosis. The CC genotype reduces the risk of venous thromboembolism 2.6-
fold, probably due to the higher APC levels observed in individuals carrying this genotype 
(Medina et al., 2004; Medina et al., 2005). 
 
TM and EPCR as candidate genes 
Pregnancy complications in patients with prothrombotic risk factors have mainly been 
linked to the formation of blood clots in placental blood vessels and sinuses, eventually 
leading to intrauterine growth retardation and, in the most severe case, foetal loss 
(Kupferminc, 2003; Kujovich, 2004; Kutteh and Triplett, 2006). Therefore, mutations in 
the genes involved in the blood coagulation systems may increase the risk of thrombosis 
and thereby miscarriage. Although the importance of the TM-protein C-EPCR system for 
placental development and maintenance of pregnancy is firmly established in mice (Healy 
et al., 1995; Gu et al., 2002), the relevance of these mechanisms for pregnancy associated 
complications in humans remains to be established. The data from mouse models, the 
known sequence homology of mouse and human TM and EPCR, and the similar type of 
placentation in both species (Dittman and Majerus, 1989; Cross et al., 1994), however, 
suggests TM and EPCR as candidate genes for RM in humans.  
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3.3.3 p53 
Functions of the p53 gene 
The p53 gene encodes a transcription factor consisting of an N-terminal transactivation 
domain, a central sequence specific DNA binding domain, and a C-terminal 
oligomerization domain (Levine, 1997). p53 is expressed
 
at low levels in most cells and 
the protein levels increase in response to various stress signals. p53 is expressed at high 
levels in the mouse embryo up to midgestation, after which the expression levels rapidly 
decrease (Rogel et al., 1985; Marzusch et al., 1995). Hundreds, if not thousands, of studies 
have been dedicated to the functions of p53 because it plays a pivotal role in tumour 
suppression. Indeed, more than 50% of human cancers contain somatic mutations in this 
gene (Levine, 1997). p53 functions as a tumour suppressor by regulating the cell cycle, 
protecting the genome from DNA damage and in inducing apoptosis. Moreover, p53 
appears to interact with a large number of proteins involved in growth control, DNA repair 
and transcriptional regulation (Choi and Donehower, 1999; Cheah and Looi, 2001; Balint 
and Vousden, 2001).  Experiments in mouse models have revealed that most of the human 
tumour suppressor genes are essential for embryonic development. Furthermore, 
inactivation of both germ line alleles of a tumour suppressor usually results in embryonic 
lethality either in early or midgestation (Rogel et al., 1985; Schmid et al., 1991; Jacks, 
1996), making p53 a candidate gene for RM. 
 
There is one previous study supporting the hypothesis that p53 has a potential role 
during early pregnancy also in humans. The results of Pietrowski et al. (2005) indicate that 
RM is associated with a polymorphism 12139G>C at codon 72, resulting in either a 
proline or arginine residue. In addition, the frequency of the Pro72 allele has been shown 
to be significantly higher among women experiencing recurrent implantation failure than 
in control women (Kay et al., 2006). The codon 72 variation of p53 have been shown to 
differ biochemically and biologically (Thomas et al., 1999), but the role of p53 and the 
codon 72 polymorphism in human development needs to be further studied. 
 
p53 mouse models 
Although p53 null mice can be viable and fertile, the absence of p53 activity can lead to 
fatal developmental abnormalities and a significant proportion of p53-/- mice die during 
embryogenesis. A substantial fraction of p53 null mice have developmental defects, 
including neural tube defects, and the affected embryos frequently undergo resorption 
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clearly implicating p53 as an important factor in the early development (Sah et al., 1995; 
Armstrong et al., 1995).  
 
p53 can inhibit DNA replication by triggering growth arrest in G1 or initiate apoptosis, 
and therefore its activity must be tightly regulated in order to allow normal growth. In the 
absence of stress inducing signals, p53 is kept at low levels via its interaction with mouse 
double minute 2 (MDM2) that binds to the transcriptional activation domain of p53. For 
cell division in the early embryo to proceed, p53 needs to be down-regulated by Mdm2 
(Piette et al., 1997; Bond et al., 2005). A deletion of Mdm2 causes embryonic lethality in 
mice around the time of implantation (Montes de Oca Luna et al., 1995; Jones et al., 
1995). In addition, p53
QS
 mutant mice, which cannot bind Mdm2 due to mutations in 
residues crucial for transactivation, show increased embryonic lethality in a homozygous 
state (Johnson et al., 2005).  
 
Mouse models have also suggested that p53 may play a key role in development 
through protecting embryos from teratogens and diverse environmental stresses (Nicol et 
al., 1995; Norimura et al., 1996). Teratogenesis experiments in mice provide strong 
support for the idea that p53 efficiently aborts embryonic cells with teratogen induced 
DNA damage. If too many cells of the embryo die through apoptosis, the entire embryo 
will die. Conversely, lack of p53 in the embryo presumably results in continued cell cycle 
progression despite DNA damage, much less apoptosis and a higher proportion of 
embryos with developmental anomalies (Nicol et al., 1995). Taken together, the results 
obtained from mouse models suggest that the relative levels of p53 in the early embryo are 
highly important, and the protein expression has to be very carefully controlled during 
developmental processes. Changes in the expression levels of p53 elevates the risk of 
miscarriage and developmental defects, and increases the susceptibility to chemical 
teratogenesis, possibly also in humans. 
3.3.4 The mitochondrial genome 
Mitochondria are cellular organelles that contain their own genome. It is estimated that in 
a somatic cell one human mitochondrion typically contains 5-10 DNA copies and, 
depending on the cell type, a somatic cell can contain up to 1,000 mitochondria. The 
human mitochondrial genome is circular, double-stranded and 16,569 bp in size. It 
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contains 37 genes; 13 protein coding genes, which are all components of the respiratory 
chain; two rRNAs; and 22 tRNAs needed for mitochondrial protein synthesis (Howell et 
al., 2000; DiMauro, 2001; Thorburn and Dahl, 2001). The mitochondria are involved in 
cellular ATP production and apoptosis (DiMauro, 2007). These processes are of great 
importance in the early development of embryos and may be disturbed by mutations in 
mitochondrial DNA (mtDNA).  
 
Genetics of mtDNA 
Mitochondrial genetics differs from Mendelian genetics in three major aspects: 
1) Maternal inheritance. At fertilization, all mitochondria in the zygote derive from the 
oocyte. mtDNA mutations are therefore inherited in a matrilineal fashion (DiMauro, 2001; 
McKenzie et al., 2004).  
2) Heteroplasmy/threshold effect. In contrast to autosomal nuclear genes, each 
consisting of one maternal and one paternal allele, there are hundreds or thousands of 
mtDNA molecules in each cell. Deleterious mutations in mtDNA usually affect some but 
not all of the mtDNA genomes. Therefore cells, tissues, and organs can contain two 
different mtDNA populations (wild-type and mutant), a state known as heteroplasmy. The 
situation when all mtDNAs are identical is called homoplasmy. Non-deleterious 
mutations/neutral polymorphisms of mtDNA are usually homoplasmic, whereas 
pathogenic mutations are usually heteroplasmic. For an mtDNA mutation to have a 
deleterious effect on tissue function it must reach a minimum threshold - a certain 
proportion of mutant molecules are required before a phenotype is observed (DiMauro, 
2001; Thorburn and Dahl, 2001; McKenzie et al., 2004).  
3) Segregation. As a heteroplasmic cell replicates different proportions of mutant 
mtDNA molecules are transmitted to the daughter cells, and when the pathogenic 
threshold for a given tissue is surpassed the phenotype can also change. In this way the 
mtDNA genotype can drift toward homoplasmy, either wild-type or mutant (DiMauro, 
2001; McKenzie et al., 2004).  
 
Today over 200 mtDNA point mutations have been reported in the Mitomap database 
(http://www.mitomap.org) to be associated with different human diseases. These 
mutations can be divided into two groups: mutations affecting mitochondrial protein 
synthesis, including mutations in tRNA and rRNA genes and mutations in protein 
encoding genes. The mutations are involved in a broad spectrum of human diseases, 
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including multisystem disorders as well as more tissue specific diseases (DiMauro, 2001; 
Taylor and Turnbull, 2005; McKenzie et al., 2004; Wong, 2007). 
 
The mitochondrial bottleneck 
The segregation of mtDNA alleles is unexpectedly rapid, and in some maternal lineages 
complete allele switching has been observed in a single generation without a 
heteroplasmic intermediate (Koehler et al, 1991). Rapid changes in mitochondrial allele 
frequencies were first observed in cattle (Olivo et al., 1983; Ashley et al., 1989) but 
similar changes have subsequently been described in many mammalian species, including 
humans. Analysis of human pedigrees segregating pathogenic mtDNA point mutations 
show large differences in the proportion of mutant mtDNAs among siblings and between 
generations (Larsson et al., 1992; Ghosh et al., 1996; Jacobi et al., 2001). 
 
The rapid changes in mtDNA allele frequency have been explained by an mtDNA 
bottleneck in the germ line, responsible for the random segregation of mtDNA sequence 
variations between generations. A mature oocyte contains about 100,000-200,000 copies 
of mtDNA (Figure 4). These mtDNA copies are randomly divided, without mtDNA 
replication, into cells of the developing embryo. Replication of mtDNA is initiated when 
the primordial germ cells (PGC) migrate and differentiate to generate oocytes. It is 
estimated that human PGCs contain ~10-100 mitochondria, increasing to ~200-1000 in the 
oogonia and to several thousands in the oocyte in the primordial follicle. As the oocyte 
matures the number of mitochondria again increases to >100,000 (Jenuth et al., 1996; 
Shoubridge, 2000; Khrapko, 2008; Stewart et al., 2008). Segregation is rapid because the 
precursor cells contain relatively small numbers of mtDNA templates and because the 
replication of mtDNA is under relaxed control. This relaxed form of replication allows 
some templates to replicate more than once during the cell cycle, while others are not 
replicating at all. Because of the mitochondrial bottleneck, the mtDNA genotype in
 
the 
embryo is largely determined by the genotype of the few
 
mitochondria in the PGC in the 
mother (Jenuth et al., 1996; Shoubridge, 2000).  
 
mtDNA in development 
The mitochondria produce the energy needed for cellular processes by producing ATP 
through oxidative phosphorylation. Through dysfunctions of energy metabolism or 
regulation of apoptosis, the mitochondria are suggested to contribute to human oocyte 
wastage and early embryo demise (Van Blerkom, 2004). The role of mtDNA mutations in 
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human early development is supported by a report describing a family with an unusual 
homoplasmic tRNA mutation that resulted in six neonatal deaths and one surviving child 
with Leigh syndrome even though the mother is clinically unaffected (McFarland et al., 
2002). As the proportion of mutant mtDNA copies can shift when inherited the phenotype 
often shows remarkable variation within a family (Ghosh et al., 1996; Blok et al., 1997; 
Jacobi et al., 2001). Accordingly, such a shift can occur from a mother with mild or no 
phenotype to an embryo with significant enrichment of mutated mtDNA causing foetal 
loss and possibly RM. Homoplasmy for a severe pathogenic mtDNA mutation is rarely 
observed, presumably because such a condition would be lethal. For example mutations 
causing mitochondrial encephalopathy with lactic acidosis and stroke-like episodes 
(MELAS) and myoclonic epilepsy and ragged-red fibres (MERRF) are invariably 
heteroplasmic and homoplasmic mutations are presumed to be fatal (Jenuth et al., 1996; 
Howell et al., 2000). An oocyte with such a mutation in a homoplasmic state would most 
likely result in foetal death at an early developmental stage. It has been suggested that this 
phenomenon might even be beneficial, if spreading of the deleterious mtDNA mutations 
that slip through the bottleneck would thus be eliminated (Bergstrom and Pritchard, 1998; 
Howell et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The mitochondrial bottleneck. During oocyte maturation a limited number of mtDNA copies are 
transferred to each primary oocyte. As this small population of mtDNA copies is rapidly replicated it may 
lead to a random shift of the mutational load in the next generation. Due to the mitochondrial bottleneck the 
offspring of a heteroplasmic female may receive a varying number of mutant mtDNA copies at fertilization 
resulting in different phenotypes; A) low level of mutation (unaffected offspring), B) intermediate level of 
mutation, C) high level of mutation (affected offspring). Modified from Taylor and Turnbull, 2005. 
  
 
 
43 
Aims 
The present study is based on hypotheses that some as yet unknown genetic factors may 
result in RM. Consequently, the main aim of this study was to gain new information about 
the underlying genetic causes of RM in the Finnish population. The aim was to identify 
candidate genes for RM and subsequently screen these genes for mutations in a series of 
samples with RM. In addition, we aimed to study if genetic factors previously reported to 
underlie RM could be the cause of RM in Finnish patients. 
 
The following specific aims were set for the study: 
 
1. To determine whether ancestral places of origin of the couples with RM show 
geographic clustering. 
2. To search for mutations in four candidate genes for RM ─ Amnionless, 
Thrombomodulin, Endothelial Protein C Receptor  and p53 ─ identified to be cruical for 
development in mouse models. 
3. To study the expression of p53 in placental samples. 
4. To search for variations associated with RM in the mitochondrial genome. 
5. To study if specific sex chromosome characteristics, namely skewed X chromosome 
inactivation or Y chromosome microdeletions, are associated with RM in Finnish patients. 
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Materials and methods  
1 Study subjects  
1.1 Patients (I, II, III, IV, V) 
The patients recruited for this study have been treated for unexplained RM at the 
Department of Gynaecology and Obstetrics of the Helsinki University Hospital during the 
years 2001-2004. The inclusion criteria for the 48 women included in the study were:  
1) age 18-40 years (mean age 31 years)   
2) previous history of RM, defined as three or more consecutive miscarriages  
3) normal karyotype  
4) no uterine abnormalities (examined by ultrasonography or hysterosonogram) 
Blood samples were obtained from male partners of 40 of the women included in the 
study. The karyotypes of these males were checked and found to be normal. Consequently, 
a total of 40 couples and 8 women with unexplained RM were included in the study. The 
women in the study had experienced three to seven miscarriages. In 45 women all 
miscarriages had taken place during the first trimester (weeks 1-12 of pregnancy). Two 
women had experienced a second trimester (weeks 13-26 of pregnancy) miscarriage, and 
one women a third trimester (from week 27 to birth) intrauterine foetal death in addition to 
first trimester losses.  
1.2 Controls (I, II, III, IV, V) 
The control group consisted of 191 healthy women who had had at least one normal 
pregnancy and no known history of miscarriage. They were recruited from the same 
hospital during the same time period as the patients. The controls were of the same age 
and racial origin (Finnish Caucasian) as the patients.  
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1.3 Placental samples (III, IV) 
One or more paraffin embedded placental sample from a spontaneously aborted pregnancy 
were available from seven of the RM women included in the study. Altogether, placental 
samples were available from 19 miscarriages. 
1.4 Ethical issues (I, II, III, IV, V) 
Informed consent was obtained from all participants prior to enrolment in the study. The 
ethics committee of the Department of Obstetrics and Gynaecology, Helsinki University 
Central Hospital, has approved this study. 
2 Methods 
2.1 Genealogic analysis  (I) 
Data concerning the birthplaces of the patients´ parents and grandparents were collected to 
determine the ancestral places of origin for the patients and to investigate if the birthplaces 
were clustered to specific regions of Finland. Data concerning the birthplaces were 
obtained through a questionnaire. Replies were received from 82 (95%) patients. To 
investigate the geographic distribution of ancestral birthplaces, the birthplaces were placed 
onto a map of Finland, including the formerly Finnish areas of Russian Karelia and 
compared to the population distribution of Finland.  
2.2 DNA extraction (I, III) 
DNA was extracted according to the manufacturer´s instructions from whole blood 
samples and paraffin sections using Puregene DNA isolation kits (Gentra Systems, 
Minneapolis, USA).  
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2.3 Candidate gene analysis  
 
Polymerase chain reaction and dHPLC sample analysis  (I, II, III, IV) 
The exons and exon-intron boundaries of the candidate genes were amplified using 
polymerase chain reactions (PCR). Amplification of appropriately sized PCR products 
were confirmed by agarose gel electrophoresis before further analysis. Mutation screening 
of the candidate genes was mostly carried out using denaturing high performance liquid 
chromatography (dHPLC) with the Transgenomic WAVE Nucleic Acid Fragment 
Analysis System (Transgenomic, Omaha, USA) and the associated Navigator software. To 
obtain optimal resolution of homoduplex and heteroduplex DNA fragments the 
temperature was set for partially denaturing conditions. The melting profile of the 
amplicons and the optimal oven temperature was predicted for each PCR fragment using 
the Navigator software. The buffer gradients for the elution of the fragments were created 
automatically with the Navigator software.   
 
To allow sequence analysis of low-level heteroplasmic mtDNA, fractions of small 
sized heteroduplex peaks were collected using an FCW-200 fraction collector integrated 
with the WAVE system. To increase the heteroplasmy level in the samples the DNA 
fractions were reamplified with the primers used to produce the original amplicon. 
 
Sequencing (I, II, III, IV) 
Following dHPLC analysis, samples showing heterozygous peaks were sequenced in order 
to determine the nature of the sequence change. PCR products were purified and 
sequenced using BigDye version 3.1 sequencing chemistry and an ABI 3730 DNA 
Analyzer (Applied Biosystems, Foster City, USA) according to the manufacturer's 
instructions. 
 
Genotype determination  (I, II, III) 
Variations that were detected in a homozygous state by sequencing were genotyped by 
restriction enzymes, sequencing, allele specific PCR, or dHPLC. 
 
Solid-phase minisequencing (IV) 
Quantification of heteroplasmy levels were performed using solid-phase minisequencing 
according to a previously described protocol (Suomalainen and Syvänen, 2000). PCR 
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products were amplified using specific primers designed for each of the variations studied. 
Biotinylated PCR products were then captured in streptavidin-coated microtiter wells and 
single nucleotide extension of specific detection primers were performed using 
radioactively labelled nucleotides. The results were expressed as numeric cpm-values, 
where the incorporated label expressed the relative amount of sequence variation in the 
sample.  
                
Quantitative real-time PCR (IV) 
The mitochondrial cytochrome b (Cytb) and the nuclear amyloid beta precursor protein 
(APP) genes were simultaneously amplified by quantitative TaqMan real-time PCR assay 
in an ABI Prism 7000 Detection System Cycler to quantify the amount of mtDNA. 
Fluorescence acquisition was done at the end of each annealing step, and the relative 
levels of the genes were compared in the exponential phase of PCR, using the ABI Prism 
7000 SDS software (Applied Biosystems). The ratio of mtDNA to nuclear DNA was used 
as a measure of mtDNA content (2
-ΔΔC
T method) (Livak and Schmittgen, 2001).  
 
Predicting the effects of variations (I, II, III, IV) 
The ESEfinder (http://exon.cshl.edu/ESE/)
 
is a web based resource which scans nucleotide 
sequences to identify putative
 
exonic splicing enhancers (ESEs), which act as binding sites 
for splicing factors. The ESEfinder was used to predict if the exonic or intronic sequence 
variations disrupt the sequence of known ESE-elements. The ESEfinder searches for 
putative ESE motifs and calculates a score for all sequences with a motif match. A 
sequence is considered to be potentially needed for splicing when the calculated score is 
greater than the threshold value defined by the program. 
 
The variations predicted to change an amino acid were analyzed by the SIFT (sorting 
intolerant from tolerant) program (http://blocks.fhcrc.org/sift/SIFT.html) which predicts 
whether an amino acid substitution in a protein will be tolerated. 
 
Different web based databases were used to determine if the detected variations have 
been previously reported; Ensemble Genome browser (http://www.ensembl.org), UCSC 
Genome browser (http://genome.ucsc.edu), NCBI Entrez SNP database 
(http://www.ncbi.nlm.nih.gov), p53 knowledgebase (http://p53.bii.a-star.edu.sg),  
Mitomap (http://www.mitomap.org), and mtDB-Human Mitochondrial Genome Database 
(http://www.genpat.uu.se/mtDB/). 
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2.4 Immunohistochemical analysis of p53 (III) 
5μm-thick sections were cut from paraffin blocks containing placental samples. The 
sections were deparaffinized in xylene and rehydrated through graded concentrations of 
ethanol to distilled water. Monoclonal antibody DO-7 directed against p53 protein 
(dilution 1:100; Dako, Glostrup, Denmark) was used as primary antibody (incubation time 
55 min). The procedure was performed in a TechMate 500 automated machine (DAB 
detection kit; Dako ChemMate). The sections were lightly counterstained with Mayer's 
hematoxylin.  
2.5 X chromosome inactivation analysis (V) 
The XCI ratio was determined in the females by analysing the methylation status of the X-
linked androgen receptor (AR). Exon 1 of the AR gene contains a polymorphic 
microsatellite with varying numbers of trinucleotide repeats (CAG)n which can be used to 
identify the different alleles of the locus. DNA was digested with a methylation sensitive 
restriction enzyme that digests only nonmethylated (active
 
X) DNA segments. Methylated 
sites can not be digested and remain intact for amplification.  
 
Fragment analysis of the microsatellite was performed using an ABI 3730 DNA 
Analyzer (Applied Biosystems). Fragment analysis data were analysed and genotyped 
using GeneMapper 3.0 software. The total fluorescent peak areas
 
for both alleles in 
digested and undigested samples were recorded
 
and used for calculation of the ratio of 
allele inactivation.
 
Previously described equations (Lau et al., 1997; Iitsuka et al., 2001) 
were used to calculate the degree of inactivation. We used both 85% (mildly skewed) and 
90% (extremely skewed) inactivation of a particular X chromosome as cut off points for 
skewed X-inactivation. 
2.6 Y chromosome microdeletion analysis (V) 
Males were screened for the presence of microdeletions using Y chromosome specific 
sequence tagged sites (STS) primer sets. Altogether, 37 STS loci spanning the whole Y 
chromosome were analysed in multiplex PCR reactions. The presence of the specific Y 
chromosome markers were shown by observing the PCR fragments on agarose
 
gels.  
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2.7 Statistical analysis (I, II, III, IV, V) 
X 
2
 and Fisher´s exact tests ([SISA 1997 programs] http://home.clara.net/sisa) were used 
for statistical analyses of the data. The odds ratios (OR) and 95% confidence intervals (CI) 
of the OR were calculated to assess the relative risk conferred by a particular allele or 
genotype. Fisher´s exact test was also used to compare the frequency of skewed XCI in the 
patient and control groups.  The T-test was used to calculate differences in mtDNA copy 
number levels after real-time PCR analyses. Differences were considered as statistically 
significant for p-values <0.05.  
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Results and discussion 
The fact that the observed incidence of RM is much higher than expected by chance alone 
suggests that RM is a clinical entity distinct from sporadic miscarriages (Regan, 1991). 
This is supported by the finding that RM tends to occur, unlike sporadic miscarriage, 
when the foetus has a normal chromosome constitution (Stirrat, 1990; Sullivan et al., 
2004). Recently, the genetic knowledge about the aetiology of diseases has expanded 
rapidly. Progress has, however, been much slower in elucidating the genetic causes of 
female infertility and RM. Although many studies have been conducted to identify the 
underlying mechanisms, the cause of miscarriage remains unknown in approximately 50% 
of cases (Plouffe et al., 1992; Clifford et al., 1994). Consequently, this study was 
conducted to gain further information about the possible genetic causes of RM in our 
Finnish patients. 
1 Genealogic studies (I) 
Genealogical studies can be used to identify geographic enrichment of genetic disorders. 
Depending on the age of the founder mutation the geographical area of such an enrichment 
can be very restricted or include large regions. In many diseases of the Finnish disease 
heritage a regional clustering of cases can still be observed, reflecting the geographical 
origins of ancestral birthplaces (Norio, 2003a; Norio, 2003b). For example, a specific type 
of ovarian failure, caused by mutations in the follicle stimulating hormone receptor 
(FSHR), called follicle stimulating hormone-resistant ovaries (FSH-RO) is an autosomal 
recessive trait which shows geographical enrichment of ancestral birthplaces (Aittomäki et 
al., 1995; Aittomäki et al., 1996). We conducted genealogic studies to investigate if such 
an enrichment reflecting a common genetic cause could underlie the miscarriages in our 
patients. The ancestors of all couples with RM were traced by questionnaires enquiring as 
to the full names, dates and places of birth of the patients´ parents and grandparents. 
Replies were received from 82 patients. To investigate the geographic distribution of the 
birthplaces, the birthplaces of the parents and grandparents were placed onto a map of 
Finland (Figure 5) and compared to a reference map showing the distribution of the 
Finnish population.   
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The results of the genealogic studies suggest the possibility of a shared underlying 
genetic defect for the miscarriages in a subset of patients. Compared to the reference map 
of the general population distribution in Finland the geographical distribution of the 
birthplaces of the parents and grandparents of the patients is uneven (Figure 5). The results 
suggest that there may be an eastern enrichment in the province of Kuopio of the ancestral 
birthplaces. In addition, the Helsinki region is over-represented, but this is explained by 
the fact that the patients were all collected from Helsinki. The clustering around Kuopio 
suggests that some of the patients may, due to common ancestors, carry a mutation 
increasing the susceptibility to RM. This would not be exceptional in Finland due to the 
population history, which has increased the local incidence of rare disorders. The special 
assortment of rare diseases among Finns is caused by the fact that the population living in 
Finland today is descended from a relatively small original population. As the population 
has increased, some alleles increased in frequency while others disappeared due to genetic 
drift, population bottlenecks, and non-assortative mating (Norio, 2003a; Norio, 2003b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Birthplaces of the A) parents and B) grandparents of 82 patients with RM. 34 of the parents and 
24 of the grandparents were born in Helsinki. The population density of Finland at the time the parents were 
born is shown in the small reference map.  
 
 
A) B) 
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2 Candidate gene analysis (I, II, III, IV) 
The results of the genealogic studies suggest a common underlying genetic cause for RM 
in at least a subgroup of our patients. Therefore, we screened a number of candidate genes 
for mutations that could possibly explain the RM experienced by the couples. The 
candidate genes AMN, TM, EPCR, and p53 were selected based on findings in animal 
models. When screening candidate genes in which homozygous mutations are expected to 
be lethal in early pregnancy, the affected foetuses cannot, in most cases, be studied 
because DNA from the spontaneously aborted foetuses is rarely available. Such mutations 
can be studied using placental tissue samples or by screening couples experiencing RM, in 
which case partners are expected to be healthy heterozygous carriers of mutations in the 
candidate gene of interest. In addition to candidate genes identified from animal models, 
the genes of the maternally inherited mitochondrial genome were chosen as candidate 
genes based on their known functions. 
2.1 Amnionless (I) 
Due to the fact that homozygous mutations in Amn are known to cause miscarriage in the 
mouse (Wang et al., 1996) and the human AMN and mouse Amn genes are highly 
homologous (Kalantry et al., 2001) AMN was considered a candidate gene for 
miscarriages in humans. Therefore, we examined whether there is an association between 
RM and sequence variations of the AMN gene in humans. To our knowledge this is the 
first study concerning the role of AMN in miscarriage. 
2.1.1 Variations in the Amnionless gene 
A total of 14 sequence variations were found by screening 85 patients (40 couples and 5 
women) with a history of unexplained RM and 95 controls for mutations in the 12 exons 
and the untranslated regions (UTR) of the Amnionless gene. Eleven of the detected 
sequence variations are intronic. Of these variations, 10 are single nucleotide substitutions, 
and one variation is a 10 basepair (GCGTGGCGTG) duplication. Three of the sequence 
variations are exonic, of which two are single nucleotide substitutions and one is a 
duplication (Table 3). None of the exonic variations detected in AMN had been previously 
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reported (databases used: www.ncbi.nlm.nih.gov; www.ensembl.org). In total, 8 novel 
sequence variations were detected in the AMN gene (Table 3). 
 
The sequence variation c.363G>A is a single nucleotide substitution in exon 5, 
changing the last nucleotide of codon 121 (GGG->GGA). It is a synonymous variation, 
detected only in patient samples and does not predict a change of the amino acid (glycine). 
Sequence variation c.829A>G is a non-synonymous SNP in exon 8, changing the first 
nucleotide of codon 276 (ACC->GCC). The variation is predicted to change the amino 
acid from threonine to alanine. According to the SIFT program this amino acid change 
would be tolerated even though the hydroxyl group of threonine makes it much more 
hydrophilic and reactive than alanine. Sequence variation c.1339_1344dup is a duplication 
in exon 12. It is a 6 basepair duplication (GCCGGG) of the codons 447 and 448, located 5 
codons before the stop codon. This DNA sequence change is predicted to make the final 
protein product 2 amino acids (Ala+Gly) longer. 
 
Table 3. The location of the variations in the AMN gene, predicted amino acid changes, and the numbers of 
patients and controls carrying the rarer allele in a hetero/(homozygous) state. Numbering of the nucleotides 
is relative to the adenine in the ATG start codon in the reference sequence (UCSC Genome Browser, 
http://genome.ucsc.edu/). 
 
AMN sequence variations     
  RM women+   
DNA variation  male partners RM women controls 
(predicted amino acid change)       Location n=85 n=45 n=95 
c.-87C>G Us 5´UTR 13 9 15 
c.-74C>T Us 5´UTR 10 8 11 
c.-27T>C Us 5´UTR 48 (15) 24(9) 50 (19) 
c.-23G>C Us 5´UTR 46 (9) 22(5) 44 (9) 
c.296-75_-66dup 
1
 intron 4 0 0 1 
c.363G>A 
1
 exon 5 4 4* 0 
c.829A>G (Thr276Ala) 
1
 exon 8 1 1 1 
c.843+11C>T 
1
 intron 8 5 5* 1 
c.1169+42C>G intron 10 43 (12) 27(6) 47 (14) 
c.1170-6C>T 
1
 intron 10 2 1 2 
c.1339_1344dup 
1
 exon 12 2 0 2 
c.1362+38G>C 3´UTR 34 (11) 22(3) 40 (14) 
c.1362+518C>T 
1
 Ds 3´UTR 0 0 1 
c.1362+523G>A 
1
 Ds 3´UTR 0 0 1 
1 
Novel variation    
Us=upstream of, Ds=downstream of 
* p < 0.05  
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Two of the novel variations; c.363G>A in exon 5, and c.843+11C>T in intron 8 were 
significantly more frequent in RM women compared to control women, indicating that 
these variations may increase the risk of miscarriage. The c.363G>A variation was 
detected in 4 RM women (8.7%) and in none of the control women (p=0.010). The 
c.843+11C>T variation was detected in 5 RM women (10.9%) and in one of the control 
women (1%) (p=0.014).  
2.2 Thrombomodulin and Endothelial Protein C Receptor (II, unpublished) 
Mutations in the TM or EPCR genes may cause thrombophilia in the mother, and thereby 
constitute a risk factor for miscarriages. In addition, homozygous mutations in the foetus 
may cause miscarriage by other mechanisms as well (Isermann et al., 2001). An important 
role for the TM-protein C-EPCR system for placental development and maintenance of 
pregnancy has been shown in mouse models (Healy et al., 1995; Gu et al., 2002). The 
relevance of these mechanisms for pregnancy associated complications in humans has, 
however, not yet been determined.  
2.2.1 Variations in the TM gene 
In this study we analysed the entire coding region of TM including exon-intron boundaries 
and the 5´ and 3´ UTRs for mutations in 86 patients with RM and 191 controls. As a 
result, one exonic and one 3´UTR sequence variation in the TM gene were detected (Table 
4). These variations were detected in both patients and controls. There were no significant 
differences in the allele or genotype frequencies between all RM patients or RM women 
and controls for either of the sequence variations in the TM gene. 
 
A novel 18 bp deletion in the 3´UTR of the TM gene, 1728+23_+40del, was detected 
in five patients (6%) and five controls (3%). The variation is located 23 bp downstream of 
the exon-intron boundary. The other variation detected in TM, c.1418C>T, is a previously 
reported common polymorphism resulting in an amino acid substitution from an alanine to 
a valine at codon 455. The variation is located in the sixth epidermal growth factor like 
domain of the gene that is responsible for thrombin binding and thereby necessary for 
protein C activation (Esmon, 1989) but has, however, previously been shown to be neutral 
in respect to thrombophilia (van der Velden et al., 1991). The variation is likely to be 
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tolerated according to the SIFT program, and was commonly detected in a homozygous 
state in both patients and controls in our study.  
 
Table 4. The location of the variations in the TM gene, predicted amino acid changes, and the numbers of 
patients and controls carrying the rarer allele in a hetero/(homozygous) state. Numbering of the nucleotides 
is relative to the adenine in the ATG start codon in the reference sequence (UCSC Genome Browser, 
http://genome.ucsc.edu/). 
 
TM sequence variations       
  RM women+   
DNA variation  male partners RM women controls 
(predicted amino acid change) Location n=86 n=46 n=191 
c.1418C>T (Ala455Val) exon 1 41 (5) 26(3) 84 (8) 
c.1728+23_+40del
1
 3´UTR 5 3 5 
1 
Novel variation  
2.2.2 Variations in the EPCR gene 
As a result of screening 86 patients and 191 controls for mutations in EPCR two exonic 
variations and two variations in the non-coding regions of the gene were detected (Table 
5). The two non-coding substitutions detected in EPCR have been previously reported as 
common polymorphisms. Variation c.323-20T>C is located 20 bp upstream of exon 3 and 
variation c.717+16G>C is located in the 3´ UTR. The c.717+16G>C polymorphism has 
been suggested to have a modifier effect on the risk of venous thromboembolism (VTE). 
Individuals homozygous for the C allele have elevated levels of activated protein C and a 
lower risk of VTE (Medina et al., 2004). In addition, a recent study suggests that the C 
allele decreases the risk of RM in women with a factor V Leiden mutation (Hopmeier et 
al., 2008).  
 
Variation c.655A>G is located in exon 4. It is a non-synonymous change, predicting a 
Ser219Gly change. The variation is predicted to be tolerated according to the SIFT 
program and previous studies have concluded that this variation does not increase the risk 
of VTE (Medina et al., 2004; Ireland et al., 2005). The 23 bp duplication, c.323-9_336dup 
in EPCR exon 3, duplicates the preceding 23 bases and results in a premature STOP codon 
downstream of the insertion point. The mutation leads to the formation of a truncated 
receptor lacking the extracellular and transmembrane domains. The truncated protein does 
not function properly because it is not localized on the cell surface, cannot be secreted 
from the cells, and does not bind activated protein C (Biguzzi et al., 2001). We detected 
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this variation in three samples; in one female patient, in one male partner, and in one 
control woman. All four variations in EPCR were detected in both patients and controls. 
There were no significant differences in the allele or genotype frequencies between all RM 
patients or RM women and controls for any of the EPCR sequence variations. Based on 
these results we cannot conclude a role for the detected EPCR variations in RM.  
 
 
Table 5. The location of the variations in the EPCR gene, predicted amino acid changes, and the numbers of 
patients and controls carrying the rarer allele in a hetero/(homozygous) state. Numbering of the nucleotides 
is relative to the adenine in the ATG start codon in the reference sequence (UCSC Genome Browser, 
http://genome.ucsc.edu/). 
 
EPCR sequence variations       
  RM women+   
DNA variation  male partners RM women      controls  
(predicted amino acid change) Location n=86 n=46 n=191 
c.323-20T>C  intron 2  41 (15) 18(11) 95 (33) 
c.323-9_336dup  exon 3   2 1 1 
(TyrProGlnPheLeuSTOP)     
c.655A>G (Ser219Gly) exon 4 22 (1) 12 49 (2) 
c.717+16G>C  3´UTR  41 (15) 19(11) 93 (34) 
2.2.3 TM/EPCR variations and outcome of heparin treatment  
Of the women included in this study, 42 had been treated with heparin and/or aspirin in 
attempts to improve the pregnancy outcome. Many of the RM women in our study had a 
full term pregnancy when treated with heparin, but not all (Ulander V-M, personal 
communication). As mutations in the TM or EPCR genes may cause disturbances of the 
uteroplacental vasculature, we investigated whether TM or EPCR variations could be 
associated with pregnancy outcome after heparin/aspirin treatment. Unfortunately, the 
number of patients in each group was too small to obtain statistically significant results 
and therefore associations between a specific TM/EPCR variation and the outcome of the 
heparin treatment could not be studied. 
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2.3 p53 (III, unpublished) 
 
p53 functions have proven important for normal development in mice. However, its role in 
human embryonic development has not been studied enough to make conclusions about its 
role at different developmental stages. As the level of p53 expression and the ability of 
p53 to interact with other proteins can be disturbed by sequence variations within the 
gene, we screened the p53 gene for variations in our series of RM patients.  
2.3.1 Variations in the p53 gene 
Nine different sequence variations were found in the p53 gene by screening 40 couples 
and 6 women with RM and 191 controls using dHPLC (Table 6). Six variations were 
confirmed by sequencing to be located in the non-coding regions, and three variations 
were found within the coding regions of the gene. All the variations have been previously 
reported as common polymorphisms (p53 knowledgebase; NCBI SNP database). Two of 
the exonic variations; G12032A, A13399G are synonymous and do not cause a change of 
an amino acid, while one of the exonic variations, G12139C, is a common non-
synonymous polymorphism changing the amino acid of codon 72 from an arginine to a 
proline. These R72P variants have been shown to differ biologically and biochemically 
(Thomas et al., 1999), and have differences in their ability to interact with basic elements 
of the transcriptional machinery, to induce apoptosis and to suppress transformed cell 
growth (Dumont et al., 2003; Pim and Banks, 2004). This variation has previously been 
studied with respect to RM. Pietrowski et al. (2005) studied 175 RM women and found an 
association between the R72P polymorphism and RM, while Coulam et al. (2006) studied 
205 RM women and showed no significant differences in the frequencies of R72P 
polymorphism between RM patients and controls. In this study, we did not detect any 
significant association between the R72P polymorphism and RM.  
 
We found the polymorphism C11992A, located 29 bp upstream of exon 4, to be 
associated with RM. The C/A and A/A genotypes of the C11992A polymorphism were 
shown to be significantly more frequent (p-value <0.05) in women with RM than control 
women. Women carrying the C/A or A/A genotype had a more than twofold increased risk 
for miscarriage (p=0.0414, OR 2.083, CI 1.018-4.259). Statistical calculations using the 
X
2
-test were performed following a dominant genotype model, where the C/C genotypes 
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were compared against the C/A and A/A genotypes. A C/A or A/A genotype was detected 
in 32.6% of the women with miscarriages and in 18.9% of the controls. When comparing 
the allele frequencies of the C11992A variation, there was no significant difference 
between the patient and control groups. 
 
 
Table 6. The location of the variations in the p53 gene, the predicted amino acid change, and the number of 
patients and controls carrying the rarer allele in a hetero/(homozygous) state. Numbering of the nucleotides 
and codons is relative to the sequence presented by the p53 knowledgebase (http://p53.bii.a-star.edu.sg) 
2005. 
 
p53 sequence variations        
  RM women+   
DNA variation  male partners RM women controls 
(predicted amino acid change) Location n=86 n=46 n=191 
11827 C>G intron 2 23 (6) 12(4) 42 (9) 
11992 C>A intron 3 22 (2) 13(2)* 29 (7) 
12032 G>A exon 4 2 0 1 
12139 G>C (Arg72Pro) exon 4  38 (8) 22(3) 77 (8) 
13399 A>G exon 6  2 1 0 
13964 G>C intron 6 0 0 2 
14181 C>T intron 7 5 3 16 
14201 T>G intron 7 5 3 16 
14766 T>C intron 9 1 0 2 
* p < 0.05 
2.3.2 p53 expression in RM placenta 
Previous studies have shown that complete absence of p53 in mice can result in lethality, 
reduced fertility, and high susceptibility to the effects of environmental stress. In addition, 
deviations in expression levels of p53 can have serious detrimental consequences (Sah et 
al., 1995; Nicol et al., 1995; Godley et al., 1996). Futhermore, a previous study showed 
higher
 
expression levels of apoptosis related genes in chorionic villi from RM patients 
compared to controls (Choi et al., 2003). To further study the role of p53 in human 
development, we studied the expression of p53 in placental tissue samples from 
miscarriages of RM patients.  
 
Placental tissue samples were available from 19 miscarriages from seven women. 
These were subjected to immunohistological staining to study the expression of p53 in the 
placenta. No abnormal expression patterns were detected in these samples (Figure 6). All 
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samples showed heterogenic and primarily weak p53 expression. Stronger expression was 
mainly seen in the cytotrophoblasts and syncytiothrophoblasts.  
 
Ten of the placental tissue samples were obtained from couples who both had a C/C 
genotype at position 11992, and 9 of the samples were from couples where one partner 
was a C/A heterozygous and the other a C/C homozygote. According to parental 
genotypes none of the pregnancies from which placental tissue were obtained were A/A 
homozygotes and hence we were not able to study whether the 11992A/A genotype would 
affect the expression of p53 in the placenta. 
 
 
 
 
 
 
 
 
 
 
Figure 6. A representative p53 staining of placental tissue obtained from a miscarriage.The expression 
patterns were similar in all 19 tissue samples. Stronger heterogeneous p53 expression is seen in the 
cytotrophoblasts and syncytiotrophoblasts. 
2.4 Mitochondrial genes (IV) 
Recent studies suggest that mitochondrial functions in the oocyte
 
may have a critical role 
in human embryonic development. Dysfunctions that affect the capacity of the 
mitochondria to produce
 
ATP or regulate the apoptosis cascade have been suggested to 
cause early demise of the embryo in humans (Van Blerkom et al., 1998; Van Blerkom, 
2004). Accordingly, we hypothesized that some women with RM could be healthy carriers 
of low-level heteroplasmic mtDNA mutations which would predispose to RM. 
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2.4.1 Variations in the mitochondrial genome  
In this study we screened 48 RM women and 48 age matched control women for 
heteroplasmic mtDNA variations using dHPLC. The method is based on detection of 
heteroduplexes in a sample and can therefore be used to detect heteroplasmic sequence 
variations. However, by sequencing a number of homoplasmic deviations from the 
reference sequence were also detected. Because all samples were not sequenced, we could 
not assess the frequency of homoplasmic changes. 
 
 
Table 7. The location of the variations in the mtDNA, predicted amino acid changes, and the numbers of 
RM women and controls carrying the variation in a heteroplasmic state. Numbering of the nucleotides are 
based on the reference sequence in the Mitomap database. 
 
mtDNA sequence variations     
DNA variation  RM control 
(predicted amino acid change) Location women women 
16362 T>C non-coding 1 0 
16519 T>C non-coding 1 1 
73 A>G non-coding 1 1 
146 T>C non-coding 1 1 
152 T>C non-coding 1 1 
195 T>C non-coding 1 0 
573 ins +1/2 bp non-coding 1 0 
4232 T>C (Ile309Thr) ND1  1 0 
4703 T>C ND2 1 0 
4722 A>G (Thr85Ala) ND2  1 0 
4727 A>G ND2 3 1 
4745 A>G ND2 1 2 
8265 T>C (Leu27Pro) CO2 0 1 
9758 T>C CO3 0 1 
11404 A>G ND4 1 0 
14653 C>T 
1
 ND6 1 0 
14569 G>A ND6 1 0 
14766 T>C (Ile7Thr) CYB  2 2 
15257 G>A (Asp171Asn) CYB  0 1 
1 
Novel variation 
 
The 19 different heteroplasmic variations detected are listed in Table 7. A 
heteroplasmic mtDNA variation was detected in 13 RM women (27%) and 9 control 
women (19%). Of the detected 19 variations, 18 have previously been reported as 
polymorphic variations in the Mitomap or mtDB database, while the variation 14653C>T, 
a synonymous change in the ND6 gene, has not been previously reported. Altogether, 12 
different variations were detected within seven mitochondrial protein coding genes. No 
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heteroplasmic variations were detected within the mitochondrial tRNA and mitochondrial 
rRNA regions. Within the non-coding control region seven heteroplasmic variations were 
detected. Seven of the variations located within the coding regions are synonymous 
changes, while five of the changes are non-synonymous, predicted to change the amino 
acid. A non-synonymous change was detected in four RM women and four control 
women. The heteroplasmy levels of the non-synonymous variations were studied using 
solid-phase minisequencing and the heteroplasmy levels are presented in Table 8. 
  
To study if the 7 variations detected in the mtDNA control region affected the mtDNA 
copy number, the mtDNA levels in samples with a variation in the control region (n=8) 
were analyzed using quantitative real-time PCR (Q-PCR) and compared to the mtDNA 
levels in samples with no heteroplasmic mtDNA variations (n=6). We did not detect 
significant differences (p=0.3568) in the mtDNA copy number between samples with a 
control region variation and control samples with no variations (Figure 7).  
 
 
Table 8. Heteroplasmy levels of mtDNA variations. 
    Level of 
Variation Sample heteroplasmy 
195 T>C RM patient 85 % 
 placenta 50 % 
4232 T>C (Ile>Thr)  RM patient 10 % 
4722 A>G (Thr>Ala) RM patient 30 % 
8265 T>C (Leu>Pro) control 75 % 
11404 A>G RM patient 10 % 
 placenta <5 % 
 placenta 15 % 
 placenta 15 % 
14653 C>T RM patient 85 % 
 placenta 65 % 
 placenta >95% 
 placenta 70 % 
 placenta 40 % 
14766 T>C (Ile>Thr) RM patient <5 % 
 RM patient <5 % 
 control <95 % 
 control <5 % 
15257 G>A (Asp>Asn) control 25 % 
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2.4.2 Analysis of placental samples 
Analysis of human pedigrees segregating pathogenic mtDNA point mutations show large 
differences in the proportion of mutant mtDNAs among siblings and between generations 
as a heteroplasmic variation is transmitted from the mother to the offspring (Ghosh et al., 
1996; Blok et al., 1997). The rapid changes in mitochondrial DNA allele frequency 
observed between generations have been explained by an mtDNA bottleneck in the germ 
line. Because of this bottleneck, the mtDNA genotype in
 
the embryo is largely determined 
by the genotype of the few
 
mitochondria in the primordial germ cell (Jenuth et al., 1996; 
Shoubridge, 2000). Due to the mitochondrial genetic bottleneck new mtDNA mutations 
are either lost during transmission or quickly reach very high levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. MtDNA copy number analysis by Q-PCR in cases with mtDNA control region variations. Eight 
lymphocyte samples and one placental sample with at least one variation in the mtDNA control region were 
compared to control lymphocyte (n=6) and placental samples (n=6) without mtDNA variations.  
 
 
To study the transmission of the mtDNA variations from the mother to the offspring 
we studied the presence of the previously mentioned variations in placental samples. 
Unfortunately, placental samples were available from only three women with a 
heteroplasmic mtDNA variation; 195T>C (1 placental sample), 11404A>G (3 placental 
samples), and 14653C>T (4 placental samples). By analyzing these 8 placental samples 
using dHPLC, we were able to show that the variations were present in the placental 
tissue. The heteroplasmy level of these variations was studied using solid-phase 
minisequencing (Table 8).  In three cases the proportion of the mtDNA variation was 
increased in the placenta compared to the mother, and in the remaining cases the 
placenta        lymphocyte lymphocyte 
    control 
placenta 
control 
MtDNA copy 
number (%) 
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proportion was decreased in the placenta. This result is similar to previous studies 
showing variable levels of heteroplasmic variations in the offspring (Ghosh et al., 1996; 
Blok et al., 1997).  
 
In addition, the mtDNA level of one placental sample with a control region variation 
was compared to the mtDNA levels in placental samples without a control region variation 
(n=6) using Q-PCR (Figure 7). No significant differences in the mtDNA copy number 
levels were detected. 
3 The impact of polymorphisms on phenotype  
Single nucleotide polymorphisms (SNPs) are the most common type of human genetic 
variation and to date over 3 million SNPs have been reported (Balakrishnan et al., 2005). 
Functional SNPs can be categorized as coding SNPs that change amino acids, and 
regulatory SNPs that modulate expression or splicing of the gene. However, the role of a 
specific polymorphism in a disease or a phenotype may be difficult to assess, especially if 
the polymorphism is located in the non-coding regions of the genome. Most 
polymorphisms are neutral but a number of SNPs in both coding and non-coding regions 
of the genome have also been reported to have phenotypic effects (Suh and Vijg, 2005; 
Balakrishnan et al., 2005). 
3.1 Variations in the nuclear genome (I, II, III, unpublished) 
Most of the variations detected in the candidate genes AMN, TM, EPCR, and p53 were 
more frequent than 1% in the control population, which is one of the definitions of a 
genetic polymorphism. In recessive disorders it is, however, not uncommon to have carrier 
frequencies of known deleterious mutations >1%, particularly in certain populations. 
Considering the frequency of miscarriage in the general population, one would expect a 
fairly high carrier frequency, if there was a relatively common mutation/variation 
underlying miscarriages. Therefore, the frequency of a possible mutation alone is not 
always a good indicator of whether a variation is a polymorphism or a mutation. It is also 
difficult to determine the function of a SNP on the basis of the nucleotide sequence alone. 
This is particularly true when the SNP neither alters an amino acid nor disrupts a well-
characterized motif that affects protein function or structure (Strahan and Read, 2004).  
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In general, nucleotide substitutions within exons may influence the function of the 
protein through changes in amino acid composition. Exonic variations that do not result in 
a change to the amino acid sequence are called silent mutations, and their phenotypic 
effect is often unclear. However, variations in the non-coding regions may also disturb or 
alter protein function. SNPs in the promoter region of a gene may influence the 
transcriptional activity of the gene by modulating transcription factor binding and 
ultimately levels of the gene product. Polymorphisms in the noncoding sequences of  
introns and the 3' and 5' UTRs may also result in defects in mRNA processing or stability 
(Rebbeck et al., 2004; Malcolm, 2005; Suh and Vijg, 2005). Recently, a growing number 
of polymorphisms within the non-coding regions of genes have been shown to alter the 
expression or the splicing of a protein (Varley et al., 1998; Attanasio et al., 2001; Wang 
XB et al., 2002; Wan et al., 2005; Bourdon et al., 2005). Therefore, some of the 
polymorphisms detected in this study may disturb the normal functions of the proteins 
encoded by the genes and thereby contribute to the etiology of miscarriage. It would be 
interesting to further study the role of some of the variations in RM, especially the 
deletion in TM, the duplication in EPCR, and the novel variations c.363G>A and 
c.843+11C>T in AMN shown to be more frequent in RM women.  
 
Although the majority of p53 mutations are missense mutations, generally causing a 
loss in the ability to bind DNA, intronic variations may also alter the function of the 
protein, or the binding sites for interacting proteins (Cho et al., 1994). Single base pair 
substitutions in intron 4 of the p53 gene have been shown to disturb the binding of 
unidentified transcription factors, resulting in decreased expression of mouse p53 
(Beenken et al., 1991). This indicates that the p53 11992 variation may also affect protein 
function. In humans, functional analysis has demonstrated elevated functional activity of 
variation G13964C in intron 6, which further indicates the importance of intronic 
sequences in regulating p53 function (Lehman et al., 2000). In addition, other intronic 
base substitutions and duplications/deletions in the p53 gene sequence have been 
associated with an increased risk for cancer, indicating that these variations may alter 
splicing, expression levels or binding sites, and thereby the function of the protein 
(Voglino et al., 1997; Wang-Gohrke et al., 1999; Lacerada et al., 2005). The mechanism 
by which the introns regulate either transcription or mRNA stability is, however, unknown 
but these results suggest that also the intronic C11992A polymorphism, which we detected 
more frequently in patients than controls, may affect the expression level of p53. 
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Alternatively, the variation may affect the protein functions required for protecting the 
embryo from teratogens and environmental stress. Further studies are, however, necessary 
to the define whether the intronic polymorphism has functional consequences and to 
determine if the association with a higher risk for miscarriage is clinically significant. 
3.1.1 Possible splice site variations 
Approximately 60% of the listed disease causing mutations are missense or nonsense 
mutations. In addition, mutations at splice sites make a significant contribution to human 
genetic diseases. Approximately 15% of disease causing mutations affect pre-mRNA 
splicing through exon skipping, activation of cryptic splice sites, creation of pseudo exons 
within introns, or intron retention (Krawczak et al., 1992; Nakai and Sakamoto, 1994; 
Baralle and Baralle, 2008). Therefore, we analysed the variations which were not 
previously defined as common polymorphisms and the novel sequence variations with the 
ESEfinder to see if any of these variations may affect splicing by altering the binding sites 
of Ser/Arg-rich (SR) proteins. The program predicted that three single nucleotide 
substitutions detected in the AMN gene and the deletion detected in the TM gene may 
affect splicing by deleting at least one binding site for known SR-proteins and may 
therefore result in exon skipping or intron retention (Table 9 and Figure 8). These 
variations may affect splicing of the gene and thereby its function. Conformation of the 
phenotypic effect of these variations, however,  requires further studies. 
 
The ESEfinder was mainly developed for analysing exonic sequences, but has also 
been used to analyze and identify mutations in introns that affect splicing (Gabut et al., 
2005; Stogmann et al., 2006). However, the program only makes predictions about the 
effect a variation may have on mRNA splicing. Thus, the presence of a high score motif in 
a sequence does not necessarily mean that the sequence determines a splicing enhancer. In 
addition, the sequences with the maximum scores are not necessarily the most effective 
splicing enhancers. The program currently searches for ESE motifs corresponding to four 
SR-proteins (SF2/ASF, SC35, SRp40, and SRp55) but there are several other SR-proteins 
for which the ESE motifs have not yet been identified (Cartegni et al., 2003).  
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Table 9. Threshold (Thr) values defined by the ESEfinder and predictive values obtained for normal and  
variant alleles for sequence variations predicted to affect the binding sites of SR-proteins. 
 
 
 
 
 
 
 
 
 
Figure 8. Diagram of the predicted values obtained by the ESEfinder for the exonic variation AMN 
c.829A>G. Graphics of the normal (A) and variant (B) sequence show that the binding site for SF2/ASF 
(black bar) present in the normal sequence (GACACCT) is abolished in the variant sequence (GACGCCT). 
3.1.2 Couple analysis 
The 40 couples included in this study were analysed to determine if some of the possible 
functional variations could be detected in both partners of a couple, thereby enabling a 
homozygous foetus. In two of the couples both partners had a different exonic or putative 
splice site affecting variation in the AMN gene. One couple had AMN variations c.363G>A 
and c.1170-6C>T, and another couple had AMN variations c.843+11C>T and 
c.1339_1344dup. In these couples there is a 25% chance for every conceptus to be a 
compound heterozygote for potentially deleterious AMN mutations in the two alleles. 
Additionally, the newly identified 1728+23_+40 deletion in TM was detected in a 
heterozygous state in both partners of one couple, enabling homozygosity of the deletion 
  SF2/ASF SC35 SRp55 
  Thr =1.956 Thr =2.383 Thr =2.267 
AMN c.829A>G    
normal allele 2.080 (GACACCT)   
variant allele <1.956 (GACGCCT)     
AMN c.843+11C>T    
normal allele 2.506 (CGCGCGG) 2.584 (GGGCCGCG)  
variant allele <1.956 (TGCGCGG) <2.383 (GGGCTGCG)   
AMN c.1170-6C>T    
normal allele  2.633 (GCCCTCAG) 2.922 (TACGCC) 
variant allele   <2.383 (GCTCTCAG) <2.267 (TACGCT) 
TM c.1728+23_+40del    
normal allele  2.742 (GGAGCCTG) 3.831 (TCCGTC) 
variant allele   sequence deleted sequence deleted 
A) B) 
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in the conceptus. This variation, located 23 bp downstream of the exon-intron boundary, 
may affect splicing, or alternatively may have an effect on the stability of the mRNA. 
Unfortunately, there were no tissue samples from miscarriages experienced by these 
couples  to study whether these variations were inherited in a homozygous form.  
3.2 Variations in the mitochondrial genome (IV) 
Although mtDNA is highly polymorphic and both pathogenic and silent variations are 
generated in the mtDNA genome, the occurrance of heteroplasmic mtDNA sequence 
variations is rare (Jenuth et al., 1996; McKenzie et al., 2004). For example, MELAS and 
MERRF mutations are invariably heteroplasmic and homoplasmic mutations in these 
genes are expected to be lethal (Howell et al., 2000). As the presence of two different 
mtDNA populations in an individual is reported to be rare (Jenuth et al., 1996; DiMauro 
and Schon, 2001; McKenzie et al., 2004), the percentage of samples with a heteroplasmic 
variation was unexpectedly high in our study. According to our study every fifth control 
woman carries a heteroplasmic variation, indicating that heteroplasmy is more common 
than previously reported. However, it may be that the high level of homoplasmy is over-
emphasized as most studies rely on techniques that cannot detect low-level heteroplasmic 
mtDNA variations (Grzybowski et al., 2000). The fact that we detected heteroplasmy in so 
many of the studied samples is most likely due to the sensitivity of the detection method 
used in our study. In 8/19 samples (42%) in which the level of heteroplasmy was tested 
the ratio of variant sequences was ≤10% or ≥90%, and could not be detected by direct 
sequencing.  
 
In this study, a heteroplasmic variation, predicted to change an amino acid, was 
detected in four RM women. All of these non-synonymous variations are previously 
reported as homoplasmic polymorphisms, and are therefore likely to be non-pathogenic. It 
is, however, possible that these variations are neutral when present in a small percentage 
of cells, but pathogenic when a threshold is reached or in a homoplasmic state. In general, 
the proportion of mutant mtDNAs in a heteroplasmic individual is expected to be very 
high before a biochemical or clinical phenotype is observed (Jenuth et al., 1996). Non-
synonymous changes in mitochondrial genes may affect ATP production or apoptosis, 
thereby leading to complications during early development. In addition, the mitochondria 
are involved in the placental progesterone synthesis required for the maintenance of 
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pregnancy (Tuckey, 2005). One of the detected coding region variations is novel, not 
previously reported in the MitoMap or the mtDB database. This variation, 14653C>T in 
the ND6 gene is, however, unlikely to be pathogenic as it does not change an amino acid. 
In addition, this variation was detected at a heteroplasmy level of 85% in one otherwise 
healthy RM woman. Consequently, this novel variation is likely to be neutral. 
 
Analysis of the mtDNA control region revealed 7 heteroplasmic mutations among RM 
patients. These variations in the most polymorphic region of the mitochondrial genome 
have previously been reported to be polymorphisms. However, mutations in the control 
region may affect replication of the mitochondrial genome and such mutations are 
suggested to be an important factor in the outcome of a pregnancy. As mitochondrial 
replication begins after implantation, replication defects
 
are not likely to compromise 
preimplantation embryogenesis,
 
but depending upon mutant load, may lead to post-
implantation
 
embryonic death (Van Blerkom, 2004). It has been reported that the 
localization of mitochondria in the early embryo is strictly regulated and the mitochondrial 
distribution is thought to play a role in defining embryonic patterning and long term 
viability of the blastomere. Therefore, mtDNA copy number may be an important 
determinant of oocyte quality as too few copies would result in maldistribution in the early 
embryo (Van Blerkom et al., 2000; Dumollard et al., 2007). To study if the detected 
control region variations is affecting mtDNA replication, we analyzed the mtDNA copy 
number in these samples. No significant differences in the mtDNA copy number were 
shown. 
4 Analysis of sex chromosome characteristics (V) 
Recent publications have reported associations between RM and skewed XCI in females 
and Y chromosome microdeletions in males. Therefore, both of these sex chromosome 
characteristics were studied in our patients.  
4.1 X chromosome inactivation analysis  
In recent years several studies have shown that skewed XCI, defined as preferential 
inactivation of one of the two X chromosomes, is increased in women with RM (Lanasa et 
al., 1999; Lanasa et al., 2001; Uehara et al., 2001; Kuo et al., 2008). Normally inactivation 
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of the X chromosomes occurs randomly on both the maternal and paternal X 
chromosomes during the late blastocyst state of embryogenesis (Lyon, 1961). The 
suggested explanation for the association between skewed XCI and RM is an unknown X 
chromosomal mutation resulting in both preferential inactivation of the mutated X and 
lethality in male embryos carrying the mutation (Lanasa et al., 1999; Uehara et al., 2001; 
Bagislar et al., 2006). 
 
To study the role of XCI in RM in our Finnish patients the XCI patterns were 
examined in 46 women with RM and 95 control women. The XCI ratio was determined by 
analysing the methylation status of the X-linked AR gene using a methylation sensitive 
restriction enzyme that digests only nonmethylated DNA segments (Figure 9). Samples 
homozygous at the AR (CAG)n locus were excluded
 
from the X-inactivation study due to 
the inability to distinguish
 
between the two alleles. 3/46 women with RM and 14/95 
control women were homozygous for the AR (CAG)n polymorphism and excluded from 
further analysis. The ratio of inactivation between the two X chromosomes was calculated 
for the remaining 43 female patients and 81 controls.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Fluorescence based X-inactivation analysis using a PCR based AR methylation assay. The 
methylation sensitive restriction enzyme HpaII digests and prevents amplification of nonmethylated (active
 
X) DNA segments.  (a) An example of equivalent inactivation of both alleles. (b) An example of extremely 
skewed inactivation of the alleles. Undigested DNA is used as control for peak intensities of the alleles. 
 
 
There are several possible reasons for the discrepancy between this study and those 
previously reported. Firstly, it is possible that the number of patients is too small to 
provide statistically reliable results if skewed XCI is the cause of RM in only a small 
subset of patients. However, previous studies have included approximately the same 
number of subjects and have been able to show an association between skewed XCI and 
undigested undigested 
Hpa II digested Hpa II digested 
a) b) 
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RM (Lanasa et al., 1999; Uehara et al., 2001). Secondly, previous studies have used 
different inclusion criteria, which may affect the results.
 
Our study included
 
patients with 
three or more pregnancy losses. In contrast, other studies have included patients with only 
two pregnancy losses (Lanasa et al., 1999; Lanasa et al., 2001; Kim et al., 2004). Finally, 
in our study the patients and controls were of same age, the mean age in both groups being 
31 years, whereas in
 
other studies the patients were significantly older than their
 
controls 
(Lanasa et al., 1999, Lanasa et al., 2001). Because skewed XCI increases in peripheral 
lymphocytes with age due to depletion of the haematopoietic stem cell pool the age 
discrepancy in other studies could have
 
resulted in a bias towards an increase in skewed 
XCI
 
in RM cases when compared with younger controls (Sharp et al., 2000; Hogge et al., 
2007).  
 
There are, however, also studies that have not detected an association between skewed 
XCI and RM (Sullivan et al., 2003; Kim et al., 2004; Hogge et al., 2007; Dasoula et al., 
2008). Beever and coworkers (2003) evaluated the XCI status in over 200 women with 
RM and did not detect an association between skewed XCI and RM. Futhermore, they 
detected a significant excess of boys in live births among women with RM, which is 
contrary to expectations if the skewed XCI is due to X-linked lethal mutations (Beever et 
al., 2003). In some women skewed XCI may be due to the limited number of precursor 
cells present
 
during the late blastocyst stage when the X chromosome inactivation process 
begins. At this developmental stage, there are approximately only 10–20 cells that will 
subsequently form the embryo; the other cells differentiate
 
into extra embryonic tissues.
 
Thus, some
 
women may show skewed XCI due to chance alone (Lyon, 1971; Belmont, 
1996; Gale et al., 1997). Alternatively, it is possible that skewed XCI is a heritable genetic 
trait that is detected
 
in family members in multiple generations. Genetic loci that influence 
the selection of the inactivated X chromosome have been detected in mice (Percec et al., 
2002; Chadwick et al., 2006).
 
Whether similar loci exist in humans
 
is not clear, but skewed 
XCI has been mapped
 
in humans to Xq28 (Pegoraro et al., 1997; Naumova et al., 1998). In 
addition, skewed XCI appears to be inherited in some families and in these families 
skewed XCI may be caused by a genetic variation that is not related to RM (Naumova et 
al., 1996).  
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4.2 Y chromosome microdeletion analysis  
To date the knowledge of male contribution to RM is largely limited to karyotyping. 
Karyotyping gives an overview of the whole genome, but reveals only large chromosomal 
rearrangements. Submicroscopic duplications and deletions, such as Yq microdeletions, 
remain unidentified using this method. Yq microdeletions are reported to cause 
spermatogenetic failure and male infertility (Vogt et al., 1996; Hopps et al., 2003). There 
are at least three regions, AZFa, AZFb, and AZFc, on the long arm of the Y chromosome, 
in which deletions are associated with varying degree of spermatogenic failure. Although 
it is widely accepted that deletions of these regions contribute to male infertility, the 
function of the genes located in the AZF regions is poorly understood (Krausz and 
McElreavey, 1999; Noordam and Repping, 2006; Ferlin et al., 2007). It has been reported 
that men with Y chromosome microdeletions have low sperm counts and a higher 
incidence of sperm chromosomal abnormalities (Foresta et al., 2005). Because sperm 
chromosome abnormalities have been found in some men of RM couples (Rubio et al, 
1999; Al-Hassan et al., 2005) Dewan and coworkers (2006) studied if Y chromosome 
microdeletions are associated with RM. They reported that a significant portion of male 
partners (82%) of women with RM had Y chromosomal microdeletions, and suggest that 
the Y chromosomal genes may be important for early embryonic development in male 
embryos (Dewan et al., 2006). 
 
In our study we investigated if a similar association between Y chromosome 
microdeletions and RM was present in our set of Finnish patients. We tested 40 male 
partners of women with unexplained RM for the presence of Y chromosome 
microdeletions. In addition, to the four STSs used in the previous study (Dewan et al., 
2006) we tested our patients using 33 additional STSs to enable the analysis of all AZF 
regions. One STS was used to test for the presence of the short arm of the Y chromosome, 
the other 32 STS loci were located on the long arm of the Y chromosome. Amplification 
products for all of the 37 STSs used were detected in all tested patients, and thereby we 
did not detect any Y chromosome microdeletions in our samples. 
 
Although our study was performed on a bigger set of samples compared to the study 
by Dewan et al. (2006), our study revealed no microdeletions and therefore does not 
support the previously reported findings. It is possible that the involvement of 
microdeletions in the aetiology of RM differs between populations and this may be the 
  
 
 
72 
cause of different results between the studies. It is known that different populations have 
different Y chromosome haplogroups and it has been shown that the susceptibility to Y 
chromosomal microdeletions varies between different haplogroups (Arredi et al., 2007; 
Yang et al., 2008). There may also be some technical problems affecting the results of the  
Dewan et al. (2006) study (Noordam et al., 2006). These technical factors could be the 
underlying cause of the discrepancy between the previously reported results and the results 
of our study. According to the NCBI UniSTS Database, the STS marker DYS262 is 
located on the short arm of the Y chromosome, and the markers DYS220, DYF86S1, and 
DYF85S1 on the long arm in the AZFc region. Dewan et al. (2006) report that they found 
patients with both DYS262 and an additional marker deleted. This indicates that these 
patients would have multiple microdeletions or alternatively a region as big as 15 Mb 
deleted. This is, however, unlikely in otherwise healthy males.  
 
According to guidelines provided by the European Academy of Andrology (EAA) and 
the European Molecular Genetics Quality Network (EMQN) for diagnostic laboratories, 
the use of 6 STSs should be able to detect up to 95% of all reported Y microdeletions in 
the AZF regions (Simoni et al., 2004). We tested our male patients using all the STSs 
recommended in the guidelines, and in addition, over 30 other markers spanning the Y 
chromosome. Therefore, it is unlikely that we would have missed at least any of the 
known deletions.  
 
Although we did not detect any microdeletions, it is important to keep in mind that a 
normal lymphocyte karyotype does not exclude sperm abnormalities. High rates of 
chromosomal abnormalities in sperm have been observed in RM patients with normal 
lymphocyte karyotypes because the highly repetitive structure of the Y chromosome 
sequence predisposes to de novo deletions (Rubio et al, 1999; Al-Hassan et al., 2005). 
This study was performed using DNA extracted from peripheral blood and therefore, it is 
possible that abnormalities leading to miscarriage have arisen in the spermatocytes during 
spermatogenesis through de novo mutations. 
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5 Limitations of the study 
When considering the known causes of miscarriages, the aetiology of RM seems very 
heterogeneous. Therefore, it is possible that mutations in the candidate genes of this study 
cause miscarriage in only a small subpopulation of couples with miscarriages and one may 
argue that more couples would be needed to determine the exact role of the candidate 
genes in RM. After excluding the common variations, the mutation rate was low in the 
candidate genes. This may be due to the fact that mutations in these genes are rare in 
general or that they are a rare reason for RM. Screening more patients and controls may 
also have revealed a statistical difference in the frequencies of the variations between 
patients and controls. Additionally, a larger number of controls would be needed to 
calculate the actual frequency of the novel variations and to determine their significance, 
as when studying recessive conditions or complex diseases some of the controls are also 
expected to be carriers of the disease causing mutation or susceptibility alleles.  
 
Additionally, we also may have missed some mutations in the candidate genes. 
Although in theory dHPLC is a highly sensitive and specific method for mutation 
detection, the sensitivity of mutation detection by heteroduplex analysis is unlikely to be 
100%. There are some rare instances where mutations may not be detected. Some 
variations can only be detected at one unique temperature, and variations located within a 
GC-rich sequence of a fragment with otherwise normal nucleotide ratios may in some 
cases not be detected due to the high melt temperature of GC-rich pockets (Xiao and 
Oefner, 2001). In this study one variation in TM (c.1418C>T) was initially not detected 
using dHPLC but by sequencing a random selection of samples. Another potential 
problem relates to the detectability of heteroplasmic mtDNA mutations in samples with a 
proportion of <5% or >95% mutant mtDNA, because heteroduplex analysis becomes 
unreliable beyond those limits (Biggin et al., 2004; Lim K et al., 2008).  
 
Another limitation of this study is the use of blood samples for detection of 
heteroplasmic mtDNA variations. It has been shown that the degree of heteroplasmy for 
some mitochondrial DNA mutations varies considerably among tissues. Studies have 
reported a decrease in the proportion of mutant mtDNA in blood by approximately 0.5% 
to 2% per year (Howell et al., 2000; Rajasimha et al., 2008; Lim et al., 2008). As a 
consequence blood may contain lower levels of the mutation compared to other tissues, 
making the detection of low-level mutations demanding.  
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Conclusions 
The aim of this study was to find new genetic causes for RM, a pregnancy complication 
that affects around 1% of couples trying to conceive. To date there are many factors 
known to cause RM, but the underlying cause of a couple´s miscarriages often remains 
unresolved as RM is a very heterogeneous condition. The identification of the underlying 
causes of miscarriage is important for developing more successful treatments for women 
experiencing RM and thereby preventing subsequent miscarriages. Identification of 
underlying causes also helps to identify pregnant women that are at a risk of having a 
miscarriage. This study aimed to identify new genetic factors underlying RM by studying 
candidate genes - either identified from animal models or regulating functions important in 
different stages of early foetal developmental - and sex chromosome characteristics 
previously reported to be associated with RM. 
 
By screening the couples for mutations in the AMN, TM and EPCR genes, two novel 
AMN variations were shown to be associated with RM. One variation, c.363G>A, is an 
exonic synonymous variation, and the other, c.843+11C>T is an intronic variation 
predicted to affect splicing. These variations may increase the risk of RM in carrier 
women. Further studies would, however, be required to confirm the phenotypic effect of 
these variations. In addition, four interesting exonic or potential splice site disrupting 
variations were detected in these genes; c.1339_1344dup and c.1170-6C>T in AMN, 
c.1728+23_+40del in TM, and c.323-9_336dup in EPCR. In one couple both partners were 
heterozygous for a deletion in the TM gene and in two couples both partners had different 
exonic or potential splice site disrupting AMN variations. These variations may play a role 
in the miscarriages of these couples. However, the phenotypic effects of the potentially 
deleterious variations cannot be determined without further investigations. It would be 
interesting to study these variatons in a larger sample set or alternatively, in 
foetal/placental samples. However, most of the variations detected in these genes are 
likely to be silent polymorphisms and, taken together, the results of this study suggest that 
mutations in AMN, TM, and EPCR do not have a major role in RM in the patients studied, 
even though their contribution to RM cannot be totally excluded. 
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Additionally, a polymorphism in the p53 gene, C11992A, was shown to be associated 
with RM in Finnish patients. The results indicate that women with a C/A or A/A genotype 
have a twofold higher risk for RM than women with a C/C genotype. As the 
polymorphism was, however, detected in a large number of controls as well it is likely to 
be a contributing factor increasing the risk of RM in combination with other sequence 
variations or environmental factors, rather than the sole cause of RM. It is also possible 
that, instead of the 11992 locus, another genetic variation linked to this locus, is the actual 
susceptibility locus increasing the risk for RM. While the exact role of p53 in development 
is unclear, it is difficult to predict whether the variation disturbs functions needed for 
normal embryonic development. The results of the p53 expression analysis indicate that 
the miscarriages experienced by the studied couples are not due to altered p53 levels in the 
placenta.  
 
When screening the mitochondrial genome heteroplasmic mtDNA variations were 
detected in 13 RM women, which was unexpected as heteroplasmic variations are reported 
to be rare. Most of these variations are previously reported as polymorphisms and the 
novel variation is likely to be non-pathogenic as it is synonymous. However, the role of 
these variations in the aetiology of miscarriage cannot be excluded as some variations may 
be pathogenic only when a certain threshold is reached. The transmission of the variations 
was studied by analysing placental samples and the result is similar to previous studies 
showing that a heteroplasmic variation in a mother is transmitted to her offspring in 
different proportions. This supports the hypothesis that a woman with no disease 
phenotype can carry a low-level heteroplasmic variation that may cause foetal death when 
transmitted to the foetus in a higher proportion. However, the variations detected in this 
study were judged to be polymorphisms, and not likely to contribute to the miscarriages 
experienced by the women studied. This, however, does not exclude the role of other 
heteroplasmic mtDNA variations in miscarriage. 
 
In this study sex chromosome abnormalities, recently reported to be associated with 
RM, were also investigated to study if these factors could underlie the RM in Finnish 
patients. The female patients were studied for skewed X chromosome inactivation and the 
male partners were studied for Y chromosome microdeletions. Based on the results of the 
study it was concluded that there is no association between skewed X chromosome 
inactivation or Y chromosome microdeletions and RM in Finnish patients. 
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Although no major genetic cause explaining the miscarriages in the patients could be 
identified, the results of the genealogic studies indicate that a subset of patients possibly 
have a common genetic cause underlying their miscarriages. The results of the genealogic 
studies suggest that there may be an eastern enrichment of ancestral birthplaces in the 
province of Kuopio, which was unexpected as the patients were collected from Helsinki. It 
would be interesting to collect more patients from this region for further genetic studies.  
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